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Endoplasmic reticulum protein 29 (ERp29) is a novel endoplasmic reticulum (ER) luminal 
protein and plays a critical role in protein unfolding and secretion. Recently, it was found that 
ERp29 is a novel tumor suppressor which drives the proliferative MDA-MB-231 breast cancer 
cells into a dormant state. However, the mechanism underlining this process is not fully 
understood. In this thesis, some aspects of the mechanism of how ERp29 induces tumor cell 
dormancy are studied. These studies provided evidence that overexpression of ERp29 induces 
breast cancer cell cycle arrest by modulating endoplasmic reticulum stress.  Overexpression of 
ERp29 down-regulates the expression of eIF2, a key ER transcription factor, and up-regulates 
the cyclin-dependent kinase, p27kip1, a tumor suppressor. High expression of eIF2 was found in 
three proliferative breast cancer cell lines -- BT549, MDA-MB-231 and SKBR3, suggesting its 
potential as a marker of tumor aggressiveness. P58ipk was also markedly increased, and appeared 
to inhibit eIF2 phosphorylation. Silencing of eIF2 in ERp29-overexpressed MDA-MB-231 
cells dramatically induces up-regulation of p27kip1. Data showed that the downstream target of 
eIF2, cyclinD1, translocated into the cytoplasm of the ERp29-overexpressed MDA-MB-231 
cells, in contrast to the accumulation of cyclinD1 inside the cell nuclei, in ERp29-silenced MCF7 
cells. Using immunofluorescence imaging, the translocation of cyclinD1 into the cytoplasm was 
shown to be phosphorylation-dependent, as phosphorylated cyclinD1 also translocated to the 
cytoplasm in the ERp29-overexpressed MDA-MB-231 while in the ERp29-silenced MCF7, 
phosphorylated cyclinD1 accumulated inside the nuclei, which facilitates tumor growth.  
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INTRODUCTION 
1.1 Breast Cancer 
1.1.1 Definition of Breast Cancer 
Normal cells reproduce themselves in a healthy way because of proper regulatory 
functions of certain genes inside their nuclei. However, if mutation occurs, some of these 
genes will be turned on while others will be turned off; leading to cells that growing and 
dividing without regulatory control and thus forming a tumor. A tumor can be benign, that is 
not harmful to health, or it can be malignant, resulting in growth out of control and spread 
across the whole body. Breast cancer,-refers to the malignant cancer that originates from 
breast cells. Breast cancer mostly originates in the cells of lobules or ducts. Cancers 
originating from ducts are known as ductal carcinomas; those originating from lobules are 
known as lobular carcinomas. It can also originate at a lesser frequency, from stromal tissues, 
which include the fatty and fibrous connective tissues of the breast.  
 
1.1.2 Incidence of Breast Cancer Worldwide 
Breast cancer is the most common cancer among women world-wide (1).In the 
more-developped countries, the breast cancer incidences are the highest (2). In 2002, It was 
estimated that 636,000 new cases occurred in developed countries and 514,000 more 
occurred in developing countries (1). Breast cancer is also the most important cause of 
neoplastic deaths among women; the estimated number of deaths in 2002 was 410,000 
world-wide (1). The incidence of breast cancer is low (less than 0.02%) in most countries 
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 from sub-Saharan Africa, in China and in other countries of eastern Asia, except Japan. The 
highest rates (0.08%-0.09%) are recorded in North America, in regions of South America, 
including Brazil and Argentina, in northern and western Europe, and Australia. (Figure 1) In 
rural areas, the rate of breast cancer is lower than the unban areas (2). 
 
Figure 1 Incidence of breast cancer world-wide.  
Data is sourced from World Cancer Report 2008, International Agency for Research on Cancer 
 
1.1.3 Incidence of Breast Cancer in Singapore 
Breast cancer is the most common cancer among Asian women (3) and among Singapore 
women (4). During 2005 to 2009, breast cancer was the top number 1 cancer with the highest 
incidence among Singapore women (Figure 2) (5). It was also the number 1 cancer resulting 
in death among females in Singapore.During the past four decades, since 1968, when 
Singapore experienced rapid economic growth and transited from a developing country to a 






Figure 2: Ten Most Frequent Cancers in Singapore Females (%), 2005 – 2009 
Data were obtained from the Singapore Cancer Registry Interim Annual Registry Report  
Trends in Cancer Incidence in Singapore 2005-2009 (5) 
1.1.4 Risk factors of breast cancer 
A wide range of genetic or life-style related factors may increase the risk of having breast 
cancer. Firstly, gender, age, and family history may play an important role. Most 
fundamentally, being a woman means that the chance of getting breast cancer is much higher 
as compared to being a man. Also, if a woman is older than 50 years of age or has a close 
relative with breast cancer, then her chance of getting breast cancer increases significantly (7). 
Exposure to the hormones such as estrogen and progesterone may also lead to breast cancer. 
Therefore, women with longer menstral periods (due to earlier onset of menstruation or later 
age of menopause) may suffer a higher risk of breast cancer. Similarly, combined hormone 
therapy involving both estrogen and progesterone exposes the subjects to greater risk of 
having breast cancer at a more advanced stage(8). Interestingly, women who never got 
pregnant or are pregnant at a later age (after 30 years old) are also at a higher risk of getting 
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 breast cancer. On the contrary, multiple pregnancies at a younger age (below 30 years old) 
reduce breast cancer risk(9).  
In order to lower the risk of having breast cancer, keeping a healthy life style is important. 
For example, consumption of alcoholic drinks increases the risk of having breast cancer (7). 
Having no more than one cup of alcoholic drink per day is thus recommended to avoid 
getting the disease. Watching one’s weight is important as well, since obese women are at 
greater risk of getting breast cancer (7).  
 
1.1.5 Stages of Breast Cancer 
 
Table 1 Staging of Breast Cancer.  
Adapted from http://www.cancer.gov/cancertopics/wyntk/breast/page7 
 
Stages Definition 
Stage 0 Cell grows abnormally but not invasive. For example, Ductal Carcinoma In Situ or 
Lobular Carcinoma In Situ 
Stage I  breast cancer. Cancer cells have invaded breast tissue beyond the original place of  
  breast. The tumor is no more than 2 centimeters across. 
Stage II The tumor is no more than 2 centimeters across. The tumor cell has spread to the 
lymph nodes under the arm. 
or 
The tumor is between 2 and 5 centimeters. But has not spread to the lymph nodes 
under the arm. 
or 
The tumor size is between 2 and 5 centimeters. And has spread to the lymph nodes 
under the arm. 
or 
The tumor is larger than 5 centimeters. But has not spread to the lymph nodes under 
the arm. 
Stage IIIA The tumor is no more than 5 centimeters across. And has spread to underarm lymph 
nodes that are attached to each other or to other structures. Or the cancer may have 
spread to lymph nodes behind the breastbone 
or 
The tumor is more than 5 centimeters across. The cancer has spread to underarm 
lymph nodes that are either alone or attached to each other or to other structures. Or 
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 the cancer may have spread to lymph nodes behind the breastbone. 
Stage IIIB A tumor of any size that has grown into the chest wall or the skin of the breast. It may 
be associated with swelling of the breast or with nodules (lumps) in the breast skin:  
The cancer may have spread to lymph nodes under the arm.  
or 
 The cancer may have spread to underarm lymph nodes that are attached to each 
other or other structures. Or the cancer may have spread to lymph nodes behind the 
breastbone.  
Or 
 Inflammatory breast cancer is a rare type of breast cancer. The breast looks red and 
swollen because cancer cells block the lymph vessels in the skin of the breast. When 
a doctor diagnoses inflammatory breast cancer, it is at least Stage IIIB, but it could 
be more advanced. 
Stage IIIC  A tumor of any size. It has spread in one of the following ways:  
The cancer has spread to the lymph nodes behind the breastbone and under the arm. 
Or 
The tumor cell has spread to the lymph nodes above or below the collarbone. 
Stage IV The cancer has spread to other organs, such as the bones or liver. 
 
 
1.1.6 Treatment of Breast Cancer 
There are many treatment options that women with breast cancer can choose from. The 
most common one is surgery, which may include removing only cancerous tissue or the 
whole breast together with some lymph node. Surgery that removes only the cancerous tissue 
is a lumpectomy or a segmental mastectomy. Surgery that removes the whole breast is called 
mastectomy. Stage 0 breast cancer can be cured by lumpectomy while stage 1 or stage 2 may 
need a mastectomy.  Besides surgery, there are other options including radiation therapy, 
hormone therapy, chemotherapy, and targeted therapy. Surgery is often combined with other 
treatment such as radiation therapy or chemotherapy. Surgery and radiation therapy are types 
of local therapy. They remove or destroy cancer cells within the breast. Hormone therapy, 
chemotherapy, and targeted therapy are types of systemic therapy. The drug enters the 
bloodstream and destroys or controls cancer throughout the body. For stage 4 metastatic 
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 cancer, surgery, radiation therapy, chemotherapy, and targeted therapies are combined to 
manage the disease. 
 
Table 2 Treatment of breast cancer.  
Content was sourced from http://www.breastcancer.org/treatment/ on 28 Mar 2011 
 
Therapy Descriptions 




Removal of only the tumor and a small amount of surrounding 
tissue. 
Mastectomy Removal of all of the breast tissue 
Prophylactic 
mastectomy 
Preventive removal of the breast to lower the risk of breast 
cancer in high-risk people. 
Prophylactic ovary 
removal 




uses extreme cold to 
freeze and kill 
cancer cells 
Uses extreme cold to freeze and kill cancer cells 
 
Chemotherapy A systemic therapy that uses medicine to go through the blood system to weaken and 





A highly targeted, highly effective way to destroy cancer cells that may stick around 
after surgery. It can reduce the risk of breast cancer recurrence by about 70%. It is 





Medicines treat hormone-receptor-positive breast cancers in two ways: by lowering the 
amount of the hormone estrogen in the body and by blocking the action of estrogen on 
breast cancer cells. It can also be used to help shrink or slow the growth of 




Types  Description 
Herceptin 
 
Works against HER2-positive breast cancers by blocking the  
ability of the cancer cells to receive growth signals 
Tykerb 
 
Works against HER2-positive breast cancers by blocking certain  




Works by blocking the growth of new blood vessels that cancer  





1.2 Endoplasmic Reticulum Stress and Unfolded Protein Response 
1.2.1. Structure and function of the endoplasmic reticulum 
The endoplasmic reticulum (ER) is a membranous organelle in eukaryotic cells that is a 
single compartment (10). Structurally distinct domains of this organelle include the nuclear 
envelope (NE), the rough ER (rER) and the smooth ER (sER) (Figure 2) and the regions that 
contact other organelles (11). The morphology of ER may not be homogenous but may differ 
in different cell types or may have different functions. The two subregions of the ER, both 
rough and smooth, are visually distinct. This may be because they contain different 
membrane proteins (10). The rough ER, with ribosomes on its surface, is the place where 
translation of a secretoty protein or a membrane protein and the cotranslational translocation 
across the ER membrane occurs. It contains signal recognition particles (SRP) which 
recognize newly synthesised polypeptide from the membrane-bound ribosome. The 
ribosome-SRP complex together with the nascent polypeptide is targeted to the ER membrane 
by interaction with the heterotrimeric SRP receptor. As translocation proceeds, the nacent 
polypeptide is translocated across the ER membrane via the macromolecular machinery 
called a translocon. Because protein translocation is important for all the eukaryotic cells, 
they all have rER. In contrast, sER only exists in certain cell types, including 
steroid-synthesizing cells, liver cells, neurons, and muscle cells. The primary activities of the 
sER are very different in each of these cell types. For example, in liver cells, the sER is 
important for detoxification of hydrophobic substances. In steroid-producing cells, it is the 
site of many of the synthesis steps. In muscle cells, it is called sarcoplasmic reticulum (SR) 
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 and is primarily involved in calcium release and uptake for muscle contraction and in neurons, 
although less well established; it is also probably required for calcium handling. Thus, the 
sER is also a cell type-specific suborganelle of the ER. 
 
 
Figure 3  Structure of Endoplasmic Reticulum.  
The picture is sourced from  
http://micro.magnet.fsu.edu/cells/endoplasmicreticulum/endoplasmicreticulum.html on December 21, 2011  
 
 
1.2.2. Definition of ER Stress 
The ER is a primary place where secretory proteins or membrane proteins are 
synthesized (11).During this process, newly synthesized proteins are folded into proper 
conformation and undergo post translational modifications such as N-linked glycosylation 
and disulfide bond formation (12). For maintaining the diverse functions of the newly 
synthesized protein, it is very important that the nascent polypeptide is properly folded to 
become a mature protein. The ER provides stringent quality control systems to ensure that 
only correctly folded proteins exit the ER and unfolded or misfolded proteins are retained and 
ultimately degraded (13). If the influx of nascent, unfolded polypeptides exceeds the folding 
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 and/or processing capacity of the ER, unfolded protein accumulate inside the ER lumen, and 
the normal physiological state of the ER is perturbed. This situation is termed ER stress. 
 
1.2.3. Unfolded Protein Response (UPR) 
When the ER suffers from ER stress, a signaling pathway called unfolded protein 
response (UPR) is activated to return the ER to its normal physiological conditions. This 
signal pathway down-regulates nascent poly-peptides entering the ER and up-regulates 
molecular chaperones to increase the folding ability of the ER (12). Also, transcription of 
genes encoding secretory proteins and translation of secretory proteins are brought down, and 
clearance of misfolded proteins are increased (14). There are mainly three transducers 
involved in the signal transduction of the UPR, namely IRE1，ATF6, and PERK (14). Firstly, 
the unfolded protein binds to the luminal domain of IRE1, triggers its autophosphorylation 
and oligomerization. It then endonucleolytically cleaves its substrate X-box binding 
protein-1(XBP-1) mRNA. The spliced mRNA is then ligated and encodes an activator of 
UPR target genes. Secondly, the activation of ATF6 leads to its transportation from the ER to 
the Golgi apparatus, and its cleavage by the Golgi-resident proteases S1P and S2P. After the 
cleavage, a cytosolic DNA-binding portion is released to enter the nucleus to activate gene 
expression. Thirdly, PERK also contains a protein kinase domain which undergoes 
autophosphorylation and oligomerization. Its activation phosphorylates its downstream target 
-the eukaryotic translation initiation factor 2-α subunit (eIF2α). This leads to the global 
translation shut down and thus prevents newly synthesized protein localization in the ER. 
Also, the phosphorylation of eIF2α activates a transcription factor ATF4 to activate more 
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 UPR target genes (Figure 4).  
 
 
Figure 4 Signal transduction of unfolded protein response.  
The picture is sourced from X Shen et al The unfolded protein response—a stress signaling pathway of the 




1.2.4 Unfolded Protein Response in Cancer 
Solid tumors are continuously challenged by a restricted supply of nutrients and oxygen 
due to insufficient vascularisation. Therefore, the stress conditions such as hypoxia, nutrient 
deprivation and pH changes, activate the UPR pathway. The UPR is a cytoprotective pathway 
but prolonged activation of UPR can lead to apoptosis (15). Under the conditions related to 
cancer formation, the role of the UPR in tumor development is ambiguous (16). The recent 
researches focused on this are summarized in Table 3. Brifely, on the one hand, some 
components of UPR, such as PERK, GRP78, and ATF4 are activated during cancer genesis to 
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 promote tumor survival (17) .Tumor cell survival is achieved by adapting the tumor cells to 
hypoxia and facilitating angiogenesis (18) or by increased expression of growth factors in 
tumor cells (19). One essential transcription factor in the UPR pathway, the XBP1, has been 
demonstrated to be necessary for cancer cell survival under hypoxia (20). The other 
component, GRP78, has also been proven to be critical for tumor cells to grow (21). 
Nevertheless, the expression level of GRP78 is shown to be significantly correlated with 
cancer reccurence and survival, with the high expression linked to higher reccurence and 
more death (22). 
On the other hand, activation of these molecules- PERK, eIF2α, GRP78 are reported to 
induce cell cycle arrest and as such suppress cancer cell growth (23) (24) For GRP78 and 
PERK, the role in cancer development is ambiguous, and awaiting further clarification. 
 
Table 3 Unfolded Protein Response(UPR) in tumor development 
Year Author Components of UPR Study Role  





axis adapts tumor cell 
to hypoxia stress 
Pro-survival 
2006 J.D. Blais, et al. PERK PERK-dependent 
translational regulation 
promotes tumor cell 
adaptation and 
angiogenesis in 
response to hypoxic 
stress 
Pro-survival 
1999 J.W. Brewer, et 
al. 
eIF2α Translational arrest 
induced via eIF2α 
phosphorylation causes 
cell cycle arrest 
Tumor suppresive 
2004 D.J. Perkins,et al. eIF2α Defects in translational 
regulation mediated by 





 antiviral activity and 
facilitate the malignant 
transformation of 
human fibroblasts 















XBP-1 XBP1 is essential for 
survival under hypoxic 
conditions and is 
required for tumor 
growth 
Pro-survival 
2007 A.S. Lee,et al. GRP78 GRP78 is highly 
expressed in tumors 
Pro-survival 
1996 C.Jamora,et al. 
 
GRP78 Knock-down of 




2006 C. Denoyelle,et 
al. 
GRP78 ER stress upregulates 








UPR activation can be mediated by three major signal transduction pathways, one of 
which includes activation of the eukaryotic initiation factor 2 α subunit(eIF2α). eIF2 is a 
multimeric protein which binds to GTP and initiator methionyl-tRNAi (Met-tRNAi), and 
mediates the association of Met-tRNAi to the 40s ribosomal subunit (25). It consists of three 
subunits α, β and γ. The α subunit, named eIF2α, has a phosphorylation unit at the Ser51 
position and its phosphorylation by PERK shuts off general translation to protect cells from 
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 ER stress (26). Meanwhile, EIF2α is a key translation initiation factor that regulates the rate 
of protein synthesis during cell proliferation. Overexpression of eIF2α is frequently found in 
tumors. For instance, expression of eIF2α was found to be positively correlated with 
classification of lymphoma behavior (27). A significantly increased expression of eIF2α in 
aggressive thyroid carcinoma exists compared to conventional papillary carcinoma (28). 
Expression of eIF2α was increased markedly in both benign and malignant neoplasms of 
melanocytes and colonic epithelium (29). Generally, eIF2α expression may have a strong 





1.3.1 Structure and Function 
ERp29 was first isolated and its cDNA cloned from rat enamel cells (30) and rat liver 
cells (31). Tissue expression of ERp29 was examined by immunoblotting (32) and northern 
blotting (31). Its expression was detected in all the tissues (32). A topology study identified 
ERp29 as an ER luminal protein known as reticuloplasmin. It was subsequently identified as 
a reticuloplasmin with an ER-retention motif, KEEL, present at the carboxyl-terminus (30). 
However, unlike other reticuloplasmins, it lacks the calcium-binding motifs and does not 
contain glycosylation sites. Moreover, it is highly homologous with members of the protein 
disulfide isomerase family, but lacks the thioredoxin-like (cys-X-X-cys) catalytic moieties 
that distinguish this class of reticuloplasmins (30). It exists mainly as a dimer and may also 
be involved in some higher-order homo- and/or heterocomplexes (33). Further research 
indicated that ERp29 is a constitutively expressed housekeeping gene which is conserved in 
all mammals (34). 
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 Under ER stress, ERp29 is drastically induced like other reticuloplasmins such as GRP78 
and GRP94. ERp29 was found to interact with the ER chaperone BiP/GRP78 (31). Two-fold 
higher levels of ERp29 were observed during the secretion of enamel proteins from the cells. 
After this period, ERp29 was down-regulated (32). These results corroborate that ERp29 may 
have an essential role in secretory-protein synthesis.  
In order to further explore the function of ERp29, an ERp29-overexpressed FRTL-5 cell 
line was established. The overexpressed ERp29 was observed to be concentrated in the ER 
microsome. Moreover, overexpression of ERp29 resulted in enhancement of thyroglobulin 
(Tg) secretion.  
On the contrary, ERp29 silencing attenuates Tg secretion (35). The overexpression of 
ERp29 can also induce the expression of ER chaperones such as GRP94, Calnexin, BiP, 
ERp72, PDI and PERK (36). The interaction of ERp29 with other ER chaperones (GRP94, 
Calnexin, BiP ERp72) and PERK was also observed.  
Overall, these findings serve to highlight the important role of ERp29 in the secretion of 
proteins from the ER.  
 
 
1.3.2 Role of ERp29 in carcinogenesis 
As a novel ER chaperone, the role of ERp29 in carcinogenesis is currently ambiguous. 
Firstly, ERp29 is found to be intensively expressed in infiltrating basal-cell carcinoma of the 
skin (37). Secondly, in a recent study, endogenous ERp29 was up-regulated in xenografts of 
MCF7 cells compared to in vitro cultured MCF7 cells. In order to further the studies, MCF-7 
cell line overexpressing wild-type or dominant-negative ERp29 were constructed, along with 
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 the mock-transfect cell line as a control. These three cell lines grew at a similar rate in vitro. 
However, xenografts expressing a dominant-negative ERp29 grew significantly less than the 
tumors from the mock-transfected cell line or cells expressing wild-type ERp29. In addition, 
morphological examination showed that tumors from wild-type ERp29 overexpressing cells 
had a more aggressive pattern as compared to tumors derived from the mock-transfected or 
ERp29-dominant negatively expressing cells. In this study, the results seem to indicate that 
ERp29 may be involved in tumorigenesis (38). 
In contrast, in another recent study, the expression of ERp29 was reduced with tumor 
progression. ERp29 overexpression led to cell cycle arrest in G0/G1 phase in the proliferative 
MDA-MB-231 breast cancer cell line. Moreover, it also led to a phenotype change and 
mesenchymal-epithelial transition. ERp29 overexpression decreased cell migration and 
reduced cell transformation.The genes involved in cell proliferation is highly reduced while 
those of some tumor suppressor are up-regulated. ERp29 is proven to negatively regulate cell 
growth in breast cancer cells (39), while silencing of ERp29 in MCF-7 cells enhanced cell 
aggressive behavior. 
Overall, the role of ERp29 in carcinogenesis is controversial, and further research is 
needed to clarify whether it is an oncogene or a tumor suppressor. 
 
1.4 Regulation of Cell Cycle 
Cell cycle is defined as the ordered process that occurs during cell division. In eukaryotic 
cells, cell cycle includes four distinctive phases- G1, G2, S and M. During the G1 phase, a 
cell synthesizes materials for cell duplication and division, followed by the S phase, in which 
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 DNA is synthesized. In the M phase, cell division occurs, leading to cell duplication. The cell 
cycle is a well regulated process in which cyclins and cyclin-dependent kinases(CDKs) play 
important roles. In the G1 phase, cyclin-D, cyclin-E, as well as cyclin-D- and 
cyclin-E-dependent kinases are critical mediators deciding whether the cell will progress 
smoothly through this phase. 
Cyclin-D1 is a well-studied G1 cyclin that regulates cell cycle progression and cell 
growth. Past studies revealed that it is exported from nucleus to cytoplasm during the S phase 
(40). Another study demonstrated that its nuclear localization is related to malignant cell 
transformation (41). Indeed, in the current study, the cyclinD1 nuclear localization in breast 
cancer cells is shown to be regulated by the key molecule-ERp29. More will be discussed in 
relation to this phenomenon in the Results and Discussion section 
 
1.5 Hypothesis  
The preliminary results in our laboratory suggest that ERp29 induces tumor cell 
dormancy in breast cancer, although the molecular mechanism under this process is not fully 
elucidated. As overexpression of ERp29 induces ER stress and activates unfolded protein 
response, whether the ER stress signaling pathway is involved in ERp29-mediated cell cycle 
arrest is still a question. Here in my thesis, we hypothesized that ERp29 induces cell cycle 
arrest in breast cancer through the ER stress signaling pathway. The aim of this research is to 
clarify what signal molecules in the ER stress signal pathway are regulated by ERp29 and 




MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Antibodies 
The following antibodies shown in Table 4 were used in western blotting and 
immunofluorescence:  




Company, country of 
manufacturing 
Used for 
Rabbit-anti-ERp29 1:2500 Acris, 
Hiddenhayse,Germany
Western Blot 
Rabbit-anti-eIF2α 1:1000 Cell Signaling 
Beverley, MD, USA 
Western Blot 
Rabbit-anti-phospho-eIF2α 1:500 Cell Signaling 
Beverley, MD, USA 
Western Blot 
Rabbit-anti-α-tubulin 1:1000 Cell Signaling 
Beverley, MD, USA 
Western Blot 
Rabbit-anti- p21Waf1/Cip1 1:100 Cell Signaling 
Beverley, MD, USA 
Western Blot 
Rabbit-anti-p27Kip1 1:100 Cell Signaling 
Beverley, MD, USA 
Western Blot 
Mouse-anti-CDKN2B 1:400 Sigma-Aldrich 
Steinheim, Germany 
Western Blot 
Rabbit-anti-ATF4 1:500 Santa Cruz 
CA, USA 
Western Blot 
Rabbit-anti-Nrf2 1:500 Santa Cruz 
CA, USA 
Western Blot 
Mouse-anti-β-actin 1:10000 Sigma-Aldrich 
Steinheim, Germany 
Western Blot 
Mouse-anti-cyclinD1/2 1:400 Upstate 
Biotechnology Inc. 








 2.1.2 Cell lines 
The human breast cancer cell lines MDA-MB-231, SKBr3, BT549 and MCF-7 together 
with non-tumorigenic cell lines MCF10A and MCF12A were purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). ERp29-transfected MDA-MB-231 
and its vector-transfected control cells were maintained in a medium supplemented with 10% 
FBS and G418 (2 mg/ml). shRNA/ERp29-transfected MCF-7 cells and its vector-transfected 
control cells were maintained in a medium supplemented with 10% FBS and G418(1 mg/ml ). 
All cells were maintained at 37 °C with 5% CO2 in a humidified incubator. 
2.2 Methods 
2.2.1 Cell culture 
MDA-MB-231 and MCF-7 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS). SKBr3 cells were cultured in 
McCoy5A medium with 10% FBS. BT549 cells were cultured in RPMI 1640 medium with 
10% FBS. The human non-tumorigenic MCF10A and MCF12A mammary epithelial cell 
lines were grown in mammary epithelial cell complete medium (MEGM), supplemented with 
bovine pituitary extract (BPE).  
To thaw frozen cells, the cells were removed from frozen storage and thawed quickly in a 
37°C water bath by gently agitating the vial. As soon as the ice crystals melted, cells were 
pipeted gently into a culture flask containing 10 ml pre-warmed growth medium. 
To subculture the cells, medium was discarded. Cells were washed with 1x ice-cold 
phosphate-buffered saline (PBS, pH7.4) to get rid of the excess medium. 1 ml of 
trypsin-EDTA was added to detach the cells. After detachment, 1 ml of FBS was added to 
neutralize the trypsin. Cells were moved into a new culture flask and 10 ml of culture 




 2.2.2 ERp29 expression vector construction 
    ERp29 of human origin was amplified using its full length cDNA, the forward primer 
(5-ATATGAATTCATGGCTGCCGCTGTGC-3’with BamHI site) and the the reverse primer 
(5’-TCAGGATCCCTACAGCTCCTCCTCTTT-3’with EcoRI site). The product of this 
reaction was ligated with pcDNA3.1 (+) vector (Invitrogen, Oregon, USA) at the BamH1 and 
EcoR1 sites. DNA sequencing confirmed the validity of the ERp29 gene. 
2.2.3 Production of ERp29-overexpressing single stable clone in MDA-MB-231 breast 
cancer cell 
The ERp29-pcDNA3.1 vector, obtained as previously described, was used to transfect 
MDA-MB-231 breast cancer cells to generate ERp29-overexpressing clones. Briefly, cells 
were cultured in a 6-well plate until 60%-70% confluence. One microgram of plasmid vector 
was diluted in Opti-MEM® reduced serum medium (Invitrogen, Oregon, USA) and mixed 
with an appropriate amount of diluted lipofectamine and then transfection was done 
according to the manufacturer’s protocol. After 48h of transfection, G418 was added to select 
positive transfectants. Serial dilutions were performed for single clone generation. The 
ERp29 expressions in these clones were confirmed by reverse-transcription PCR and 





2.2.4 Buffer preparation 
2.2.4.1 1X SDS electrophoresis running buffer 
 Final Concentration  Amount 
Tris-base  25mM 3.03g 
Glycine 192mM 14.40g 
SDS  0.1% (w/v) 1.0g 
Milli-Q Water  To 1L 
 
2.2.4.2 1X western blot transfer buffer 
 Final Concentration Amount 
Tris-base 25mM 3.03g 
Glycine 192mM 14.40g 
Methanol 20%(v/v) 200ml 
Milli-Q Water  To 1L 
 
2.2.4.3 RIPA(Radio-Immunoprecipitation Assay) buffer: 
                  1% Igepal  
                  1% sodium deoxycholate 
                  0.15 M sodium chloride 
                  0.01 M sodium phosphate, pH 7.2 






 2.2.5 Casting of denaturing polyacrylamide gels  
2.2.5.1 Compositions for the 10%and 12% resolving gel 
 10%(ml) 12%(ml) 
30% acrylamide 3.33 3.96 
1.5M Tris-HCl, pH 8.8 2.5 2.5 
Milli-Q water 4 3.39 
10% SDS 0.1 0.1 
10% APS 0.05 0.05 
TEMED 0.007 0.005 
Total  10 10 
 
2.2.5.2 Compositions for the 4% stacking gel 
 4%(ml) 
30% acrylamide 0.66 
1M Tris-HCl,pH7.0 1.26 
Milli-Q water 3 
10% SDS 0.05 




2.2.6  Western blotting  
2.2.6.1  Total cell lysates 
When cells were grown to 80% confluence, the medium was discarded and then washed 
with PBS. After the remaining medium was washed off, cells were treated by trypsin-EDTA 
and then collected into a microfuge tube. The cell pellet was washed three times with ice-cold 
phosphate-buffered saline (PBS, pH 7.4). Cells were then resuspended in cold RIPA buffer 
pH7.4 supplemented with protease inhibitors and phosphatase cocktail inhibitors I and II and 
kept on ice for 1 hour. Cell lysates were then centrifuged at 4oC at 12000 rpm, and the 
supernatants containing the total cell lysate proteins were collected. 
 
2.2.6.2 Protein concentration measurement 
Protein concentrations were determined using the Coomassie Plus Bradford assay (Pierce, 
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 Rockford, IL) In each cuvette, 50 μl of protein extracts were diluted by 450 μl of 
sterilized water, and then 1 ml of Coomassie Blue reagent was added into the cuvette. The 
sample was incubated for 10 min and its protein concentration was determined using a 
spectrophotometer (Beckman Coulter DU® 800,VWR).  
 
2.2.6.3 Running an SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis) gel 
10-12% SDS-PAGE gels were prepared for protein electrophoresis (refer to Tables 
2.2.3.1 and 2.2.3.2). 40 μg of the total protein with loading dye (Laemmli loading dye),  A 
3X stock comprises of: 1M Tris-HCl pH 6.8, 2.4 ml 20% SDS, 3 ml Glycerol (100%), 3 ml 
β-mercaptoethanol, 1.6 ml Bromophenol blue (0.006g) was loaded into each well of the 
SDS-PAGE gel and run using the Mini-PROTEAN 3 Electrophoresis Cells (Bio-Rad, 
Hercules, CA, USA) under 70 V for 30 min and 100 V for 1 hour until the dye front reached 
the edge of the gel.  
 
2.2.6.4 Transfer of proteins to PVDF membrane  
The proteins were then transferred onto a Hybond-P Polyvinylidene Fluoride (PVDF) 
membrane (GE Healthcare, Uppsala, Sweden) using the wet transfer apparatus (Bio-Rad, 
Hercules, CA) at 100 V for 1 h. 
 
2.2.6.5 Antibody hybridization 
After complete transfer was effected, the membrane was washed using Tris-buffered 
saline containing 0.1% Tween-20 (TBS-T) and blocked with 5% non-fat milk (Santa Cruz 
22 
 
 Biotechnology, Inc., CA, USA) in TBS-T at room temperature for 1 h. The membrane was 
then incubated overnight with respective antibodies at 4ºC. TBS-T was used to wash off the 
unbound excess primary antibodies. Then, secondary antibodies – the HRP-conjugated goat 
anti-mouse IgG (Molecular Probes, Invitrogen, Oregon, USA) at 1:5000 dilutions in TBS-T 
or HRP-conjugated goat anti-rabbit IgG (ZYMED Laboratories Inc. San Francisco, CA, 
USA) at 1: 10 000 dilutions in TBS-T were applied for 2 hours and TBS-T was used to wash 
off the unbound secondary antibodies.  
 
2.2.6.6 Signal detection 
The chemiluminescent signals were detected using the SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Signals were then captured with 
the MULTI GENIUS BioImaging System (Syngene, Frederick, MD, USA) and the signal 
intensities were analyzed using the GeneTools software (Syngene, Frederick, MD, USA). The 
same membrane was then stripped and reprobed with anti-β-actin antibody which was the 
control to normalize for even protein loading. 
 
2.2.7 Immunofluorescence and confocal microscopy 
The cells were grown on glass coverslips using a 6-well plate. In each well, three glass 
coverslips were placed. After cells were grown for 24 h, they were washed with warm PBS at 
at ~37C. The cells were then fixed with 4% paraformaldehyde (Sigma-Aldrich, Steinheim, 
Germany) in PBS for 30 min.  After fixation, the cells were washed with PBS and then 
permeabilized with 0.1% Triton X-100 for 10 min. The cells were washed with 0.02% PBS-T 
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 and blocked with 3% bovine serum albumin (BSA) in PBS-T for 1 h. After that, cells were 
incubated with anti-CyclinD1/2 primary antibody over-night at 4℃ with gentle shaking. The 
cells were then washed with 0.02% PBS-T and then incubated with Alexa Fluor® 488 (1:200 
dilution, Invitrogen, Inc., Carlsbad, CA) for 2 h. Slides were mounted using the antifade 
mounting fluid containing DAPI and the images were visualized and captured using the 
Olympus Fluoview FV500 fluorescent microscope (Olympus, Japan). Raw images were 
analyzed using the Olympus FV10-ASW Viewer Software (Olympus, Japan). 
 
2.2.8 siRNA treatment 
siRNAs against p38 (sip38, SignalSilence® p38MAPK siRNA II, #6243) was purchased 
from Cell Signaling Technology® (Beverley, MD, USA). siRNA against eIF2α (eIF2α 
siRNA(h), sc-35272) and control siRNA (Control SiRNA-A:sc-37007) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). MDA-MB-231 cells were plated in six 
well plates and grown to about 50% confluence before treatment with siRNA at a final 
concentration of 100pM with LipofectAMINE 2000 (Invitrogen) according to the 
manufacturer's protocol. Cells were collected at 48 h post-transfection and the inhibition of 
p38 and eIF2α by siRNA was verified by Western blotting (see section 2.2.4). 
2.2.9 Statistical method 
Student’s T-test is used for analyzing data. The student T-test is done by an online calculator 








3.1 ERp29 regulates transcription factor eIF2α and Nrf2 in ER stress signaling 
 
eIF2α is an important translation initiation factor. Its phosphorylation regulates global 
protein synthesis (42). It is known that ER stress signaling of PERK/p-eIF2α translationally 
regulates protein synthesis and induces G1 arrest by phosphorylation of eIF2α (43). In order 
to explore how ERp29 modulates ER stress signaling, MDA-MB-231 cells stably 
overexpressing ERp29 were used. Total proteins were extracted from this cell line and the 
respective control cell line, and the level of ERp29 was detected by Western blotting. (Fig 5 
left panel) In this (MDA-MB-231) clone, expression of ERp29 was nearly two-fold higher 
than the mock-transfected cell line. Western blots performed to examine the expression level 
of eIF2α, showed it was down-regulated in conjunction with ERp29 overexpression (Figure 5 
left panel ) Meanwhile, knock-down of ERp29 in the MCF7 cell line slightly increased the 















Figure 5. ERp29 overexpression down-regulates translation initiation factor eIF2α. 
Western blotting was performed using protein lysate from ERp29 overexpressing MB231 
cells(left panel,ERp29) together with ERp29 silenced MCF7 cells(right panel,P2).40ug 
protein was loaded in each well and separated by SDS PAGE. The expression of basal eIF2α 
together with its phosphorylated form were examined using anti-eIF2α antibody (or 
anti-phosphoSer51-eIF2α antibody (Cell Signaling, USA) .β-actin is used as a loading 
control.  
 
However, it is found that over-expression of ERp29 did not markedly enhance the 
relative phosphorylation of eIF2α (p-eIF2α/eIF2α) in ERp29-overexpressing MDA-MB-231 
cells. Instead, the basal level of eIF2α was markedly reduced by ERp29. These data indicate 
that overexpression of ERp29 in MDA-MB-231 cells disturbs ER stress signaling by 
affecting the basal expression of eIF2α rather than by regulating its phosphorylation. Also, 
eIF2α is an important translation initiation factor which controls global protein synthesis. As 
such, the results so far appear to show that ERp29 may play a role in tumor dormancy by 
decreasing the level of eIF2α to suppress the cellular protein synthesis for energy 
conservation. 
Besides eIF2α, another transcription factor which acts down-stream of PERK, the NF-E2 
related factor 2 (Nrf2), which is ubiquitously expressed and responds to oxidative stress 
within cells, has also been studied. A role for Nrf2 activation during the UPR was established 
following the identification of Nrf2 as a PERK substrate (44). It was found that 
PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival 
following Endoplasmic Reticulum Stress. Some preliminary results have shown that the level 
of ERp29 is highly reduced in highly proliferative cancer cells such as MDA-MB-231 when 
compared to MCF7 cells which on the contrary are low-proliferative cells (39). Moreover, 
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 over-expression of ERp29 in MDA-MB-231 and SKBr3 strongly inhibited cell growth (39). 
On the other hand, knock-down of ERp29 in the MCF7 cell line promoted cell proliferation 
(39). Thus, it may be concluded that ERp29 suppresses cell growth in breast cancer cells to 
induce dormancy. However, the molecular mechanism underlying this phenomenon is not 
fully understood. Therefore, in the current dissertation, the author attempt to investigate how 
ERp29 may regulate another effector of PERK, Nrf2 in breast cancer cell lines. The levels of 
eIFα and Nrf2 in a panel of breast cancer cell lines including the non-tumorigenic MCF10A 
and MCF12A cells, low-proliferative MCF7 cells and high-proliferative MDA-MB-231, 
SKBr3 and BT549 cells were examined.  As shown in Figure 6 and Figure 7, eIF2α and 
Nrf2 are highly increased in high-proliferative MDA-MB-231, SKBr3 and BT549 cells when 
compared with the low-proliferative MCF7 cells.  
 
Figure 6. Expression of eIF2α in breast cancer cell lines Total protein was extracted from a 
subset of breast cancer cell lines. Western blot was performed using anti-eIF2α antibody. 


































Figure 7. Expression of Nrf2 in breast cancer cell lines Total protein was extracted from a 
subset of breast cancer cell lines. Western blotting was performed using anti-Nrf2 antibody. 
β-actin is used as a loading control. Nrf2 expressed most high in MB231 cell line. 
 
 
Since the ERp29 expression is low in MDA-MB-231, ERp29 was overexpressed in this 
cell line to determine whether the Nrf2 expression will be altered. As expected, Nrf2 is 
down-regulated when there is ERp29 overexpression (Figure 8). ERp29 was also knocked 
down in MCF7 which showed the highest ERp29 expression among the panel of cells 
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 examined (39). However, the level of Nrf2 did not increase as predicted. This could be due to 
insufficient knock-down of ERp29 for this cell line, or due to the possibility that the 
mechanism of regulation for Nrf2 in MCF7 is different from that in other cell lines. To further 
investigate for these findings, ERp29 was also knocked down in MDA-MB-231 and the 
expected increase in expression of Nrf2 was observed (Figure 9). 
 
Figure 8. Expression of Nrf2 in ERp29 overexpressing MB231 or ERp29 silenced MCF7. 
Total protein lysates was extracted from ERp29 overexpressed MB231(clone B, clone C and 
clone E) or ERp29 silenced MCF7(clone P1, cloneP2 and cloneP3). Western blotting was 
performed using anti-Nrf2 antibody(Santa Cruz, USA) . Data shown represent the average 





Figure 9. Expression of Nrf2 in ERp29 silenced MB231(A3) . Total protein lysate from 
mock-transfected control cell line(PC) or ShRNA transfected ERp29 silenced MCF7 cell line 
were used for Western blotting, data shown represent the average from triplicate experiments. 
β-actin was used as a loading control.  
 
3.2 ERp29 overexpression regulates cell cycle mediators and inhibitors in breast cancer 
Transitions between cell cycle phases are regulated by the activity of specific 
cyclin-dependent kinases (CDKs). Among them, CDK1/CDK2 regulates G2/M phase 
transition while CDK2/CDK4/CDK6 regulates G1/S phase transition. CDK protein 
expression levels stay constant throughout the cell cycle, while their binding partners (such as 
cyclins) and post-translational modifiers (including kinases and phosphatases) undergo 
periodic oscillations to regulate DNA synthesis and cell division. In breast cancer, cyclin D1 
and E, as well as the CDK inhibitors p21 (Waf1/Cip1; hereafter referred to as p21) and p27 
(Kip1; hereafter referred to as p27) are important in cell-cycle control and as potential 
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 oncogenes / tumor suppressor genes. They are regulated in breast cancer cells following 
mitogenic stimuli including activation of receptor tyrosine kinases and steroid hormone 
receptors, and their deregulation frequently impacts on breast cancer outcome, including 
response to therapy. It will be interesting to examine how ERp29 overexpression regulates the 
key cyclins or cyclin-dependent kinases and impacts the cell cycle progression in breast 
cancer. Gene array was performed to measure relative changes in transcription of cell cycle 
regulatory proteins. As shown in Figure 10B, the expression of kinase inhibitor p15 is 
dramatically up-regulated by 719.3 fold, while on the other hand, the expression of cyclinD2 
is significantly down-regulated by 162.4 fold. Western blot results showed that cyclins D1/2 
were down-regulated and degraded with ERp29 overexpression (Figure 10A and Figure 12). 
Meanwhile, the expressions of cyclin-dependent kinase inhibitors p15/p21/p27 were 




Figure 10 Expression level of important cell cycle regulators. A. Total protein lysates 
extracted from ERp29 overexpressing and silenced MB231 and respective control cell lines 
were examined by immunoblotting. Anti-cyclinD1/2 antibody was used in immunoblotting. 
Βeta-actin was used as a loading control. B.Gene array data showing key cyclins, 
cyclin-dependent kinase and cyclin-dependent kinase inhibitor which was regulated by 
ERp29 overexpression 
 
Figure 11 ERp29 regulates CDK inhibitors. Total cell lysates from ERp29 overexpressing 
MDA-MB-231(B and E)and ERp29 silenced MCF-7 and their respective control cell line was 
extracted. Western blot was performed using anti-p15, anti-p21,anti-p27 and anti-ERp29 





Cyclin D1 and cyclin D2 are key mediators regulating G1/S transition through formation 
of complexes with Cyclin-Dependent Kinases (CDKs) to promote cell cycle progression. On 
the contrary, CDK inhibitors p15, p21 and p27 inhibit cell cycle progression from G1 phase. 
Therefore, ERp29 may down-regulate G1 cyclins (Figure 12) and up-regulate CDK 
inhibitors(Figure 11) to induce cell cycle arrest in G0/G1 phase for dormancy to commence.  
 
Figure 12 ERp29 regulates G1 cyclins in MDA-MB-231 and MCF7. Total cell lysates 
from ERp29 overexpressing MB231 (B and E) and ERp29 silenced MCF7 (shERp29) was 
examined by Western blotting. Anti-cyclinD1 and anti-cyclinD2 were used in Western 
blotting. Βeta- actin was used as a loading control.  
 
While it is shown that ERp29 up-regulates CDK inhibitors to induce cell cycle arrest, the 
pathway involved in this regulation is however still unknown. As it was previously found that 
the key translation initiation factor eIF2α is down-regulated with ERp29 overexpression, it is 
possible that this down-regulation may induce heightened expression of CDK inhibitors. To 
test this hypothesis, eIF2α was knocked down in MDA-MB-231 breast cancer cells and the 
expression of the CDK inhibitor p27 was examined. As shown in Figure 13, when eIF2α was 
silenced in MDA-MB-231, the expression of p27 increased. Therefore, the results indicate 


































Figure 13 Silencing of eIF2α up-regulates p27 expression. Cells were transferred to grow 
in 6-well plate to 50% confluence and were transfected with eIF2α SiRNA, after 48 hours, 
cells were detached by trpsin and cell lysates were collected and subject to western blot.  
Both expression of eIF2α and p27 were examined using respective antibody. α-tubulin was 
used as a loading control.  
 
3.3 ERp29 regulates cellular localization of the cell cycle regulator cyclinD1 
Increased levels of cyclin D1 occur in a large segment of human cancers. Amplification 
of the cyclin D1 locus accounts for a low proportion of the total number of cancers that 
overexpresses cyclin D1; the mechanisms contributing to cyclin D1 overexpression in the 
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 remainder have not been firmly established as yet. Notably, a large body of work strongly 
suggests that enforced overexpression of cyclin D1 is not likely to be the essential 
transforming property of cyclin D1. More recently, work has revealed that expression of a 
cyclin D1 mutant that is refractory to nuclear export and proteolytic degradation at the G1/S 
boundary is a highly transforming mutant and functions independent of additional oncogenes 
in vitro. 
As discussed above, ERp29 down-regulates cyclinD1/2 expression in breast cancer cells, 
but the mechanism underlying this process is unknown. Also, it remains to be seen whether 
ERp29 regulates cyclinD1/2 subcellular localization. An immunofluorescence study was 
performed to determine the location of cyclinD1/2 with ERp29 overexpression or knock 
down. As shown in Figure 14, cyclinD1/2 is localized in both the nucleus and cytoplasm in 
the vector-transfected MDA-MB-231 control cells, while it is translocated from nucleus to 







Figure 14 ERp29 regulates cyclinD1/2 subcellular localization in MDA-MB-231 cells. 
MDA–MB-231 cells(control-EV, B, E) were cultured in a 6-well plate with coverslips. After 
cells attaches onto the coverslip, discard medium and remove the coverslips from wells. Cells 
were fixed with 30μl of 4%paraformaldehyde for 30 min and then washed with PBS. Cells 
were then permeabilized using 30μl of 1% Triton-x-100 for 10min.After wash with 0.02% 
PBST, cells were then blocked with 3% BSA for 1 h in room temperature. After blockage, 
cells were incubated with anti-cyclinD1/2 antibodies at 4℃ overnight and then incubate with 
secondary antibodies for 1 hour. Cells were then incubated in dyes for 30min. Following 

















Figure 15 ERp29 regulates cyclinD1/2 subcellular localization in MCF7 cells. MCF7 
cells (control-EV, P2) were cultured in a 6-well plate with coverslips. After the cells attached 
onto the coverslip, discard the medium and remove the coverslips from wells. Cells were 
fixed with 30μl of 4%paraformaldehyde for 30 min and then washed with PBS. Cells were 
then permeabilized using 30 μl of 1% Triton-x-100 for 10min.After washing with 0.02% 
PBST, cells were then blocked with 3% BSA for 1 h at room temperature. After blockage, the 
cells were incubated with anti-cyclin D1/2 antibodies at 4℃ overnight and then incubated 
with secondary antibodies for 1 hour. The cells were then incubated in dyes for 30min. 
Following which the coverslip was mounted and sealed.  
 
As cyclinD1 nuclear export is phosphorylation dependent, phosphorylated cyclinD1 
subcellular localization was examined. As shown in Figure 16, phosphorylated cyclinD1 
remained inside the nucleus of the vector-transfected MDA-MB-231. During the onset of 
tumorigenesis, tumor suppression breaks down when the cell is no longer capable of shuttling 
phosphorylated cyclinD1 from the nucleus during the S-phase (41). With the phosphorylated 
cyclin D1 being retained in the nucleus, the former can lead to cell cycle progression and 
consequently uncontrolled cancerous cell growth. The mechanism underlying crippling of 
cyclin D1 nuclear export in MDA-MB-231 is currently unknown but may result from direct 
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 mutations within cyclin D1 or mutations that target the upstream signaling pathway that 
regulate nuclear export of cyclin D1 complexes. In the current dissertation, it was found that 
overexpression of ERp29 leads to nuclear export of phosphorylated cyclinD1. As shown in 
the published results (39), ERp29 overexpression suppressed tumor cell growth and caused 
cell cycle arrest in the G0/G1 phase, and this is likely to be due to ERp29-induced cyclinD1 
export. Therefore, these data suggest that ERp29 can suppress tumor growth for dormancy 
induction not only through down-regulation of cyclinD1 expression, but also by regulating its 
subcellular localization.  
  
Figure 16 ERp29 regulates cyclinD1 nuclear export in MDA-MB-231 cells. MDA –MB-231 
cells(control, B, E) were cultured in a 6-well plate with coverslips. After cells attached onto the coverslip, 
discard the medium and remove the coverslips from wells. Cells were fixed with 30μl of 
4%paraformaldehyde for 30 min and then washed with PBS. Cells were then permeabilized using 30μl of 
1% Triton-x-100 for 10min.After washing with 0.02% PBST, cells were then blocked with 3% BSA for 1 h 
at room temperature. After blockage, cells were incubated with anti-cyclinD1/2 antibodies at 4℃ 
overnight and then incubate with secondary antibodies for 1 hour. Cells were then incubated with dyes for 














Figure 17 ERp29 regulates cyclinD1 nuclear export in MCF7 cells. MCF7 cells(control, P2) was 
cultured in a 6-well plate with coverslips. After cells had attached onto the coverslip, discard medium and 
remove the coverslips from wells. Cells were fixed with 30μl of 4%paraformaldehyde for 30 min and then 
washed with PBS. Cells were then permeabilized using 30μl of 1% Triton-x-100 for 10min. After washing 
with 0.02% PBST, cells were then blocked with 3% BSA for 1 h at room temperature. After blockage, cells 
were incubated with anti-cyclinD1/2 antibodies at 4℃ overnight and then incubated with secondary 
antibodies for 1 hour. Cells were then incubate with dyes for 30min. Following which the coverslip was 
mounted and sealed. The arrow indicates cytoplasm phospho-cyclinD1 
 
3.4  ERp29 up-regulates ER stress induced molecular chaperone p58IPK   
p58ipk is an ER resident chaperone which is induced during the UPR. Previously it has 
been shown that over-expression of ERp29 in MDA-MB-231 led to activation of XBP-1, one 
of the ER proteins that regulate p58ipk  (45). p58ipk may interact with PERK and attenuate 
PERK-mediated eIF2α phosphorylation under conditions of stress. Under the condition of 
cancer, it may be activated to cope with the ER stress. In the current study the aim is to 
determine if ERp29 overexpression can modulate ER stress signaling in breast cancer cells to 
induce tumor cell dormancy. As such, Western blot was performed to determine if p58ipk is 
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 regulated by differential expression of ERp29. As shown in Figure 18, in ERp29 
overexpressing MDA-MB-231, the expression of p58ipk is markedly enhanced. On the other 
hand, ERp29 knock-down in MCF7 cells down-regulated its expression. The up-regulated 
p58ipk functionally counteracts the upsteam kinase of eIF2α to inhibit its phosphorylation 
and attenuates activation of the p-PERK/p-eIF2α pathway.  
PERK is a type-I ER transmembrane protein. It has a luminal domain bound by the ER 
chaperone BiP/GRP78 in non stress conditions. It also has a cytoplasmic domain containing 
kinase activity. Upon ER stress, BiP releases the luminal domain of PERK, allowing PERK to 
dimerize and autophosphorylate to become active (17). PERK activation then directly leads 
to eIF2a phosphorylation at Ser51 and translation inhibition (17).Some of the effects of 
PERK are mediated through the transcription factor ATF4, which is translationally 
upregulated by ER stress in an eIF2a phosphorylation-dependent manner (17). 
Interestingly, in addition to p58ipk, it has been observed that expression of basal PERK 
was highly increased whereas phosphorylation of PERK was weakly detectable in ERp29 
overexpressing dormant cells as compared to the control cells (Figure.18B, left panel). It is 
reasonable that inactivation of PERK is mostly due to the increased level of p58ipk which 
binds to PERK and represses PERK phosphorylation. Over-expression of ERp29 increased 
the expression of BiP/GRP78 in the ERp29 overexpressing MDA-MB-231 cells. However, 
knockdown of ERp29 in MCF-7 cells also resulted in an increase of BiP/GRP78. 
Furthermore, expression of the eIF2α phosphorylation-dependent transcription factors ATF4 
was not changed in the ERp29 overexpressing dormant cells. In contrast, knockdown of 
ERp29 in MCF-7 cells activated the expression of ATF4, consistent with the enhanced eIF2α 
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 phosphorylation in the ERp29-knockdown MCF-7 cells. (Figure 5 right panel) These results 
indicate that the ER-dependent pro-apoptotic signaling is markedly suppressed by ERp29 in 
these dormant cells. 
 
Figure 18. ERp29 modulates ER stress signaling.  Total cell lysates were extracted from ERp29 
overexpressing MDA-MB-231 cells (B) or ERp29 silenced MCF7 cells(shERp29). Western blot was 
performed using anti-p58IPK, anti-PERK, anti-p-PERK, anti-BIP and anti-ATF4 antibodies. β-actin 




 Chapter 4 
DISCUSSION 
Organisms across different kingdoms have evolved ways to sense unfavorable 
environments and cope with stressful conditions (e.g., drought, cold, nutrient deprivation or 
heat shock) in order to survive. This in turn results in a suspension in development or growth 
and in the manifestation of stress-resistant phenotypes. These machineries provide organisms 
an adaptive advantage to resume development and/or growth after the stress is eased, as such 
they can generate offspring. This stage is defined as dormancy in plants, diapause in 
nematodes or hibernation in mammals. 
      Cancer recurrence is frequent - for example, 20-45% of patients with breast or 
prostate cancer will relapse years or decades later (46). Recurrence may, to some extent, be 
due to the presence of solitary dormant cancer cells. It is not common for disseminated cells 
that arrived in a secondary site to proliferate or even form large metastases of clinical 
importance. In fact, most cells that arrive at a secondary site will undergo apoptosis or remain 
in the tissue as solitary dormant cells (47). These cells are defined as quiescent cells which do 
not proliferate nor undergo apoptosis. In breast cancer, metastasis can occur many years after 
treatment. Though chemotherapy is used to prevent metastatic recurrence, it is not always 
successful. This is due to a large number of dormant cells which are disseminated in vivo and 
which are not sensitive to be killed by chemotherapy (48). The longest interval between 
primary treatment of breast cancer and tumor recurrence can be 20 to 25 years (46). A lack of 
insight into the mechanism of cancer cell dormancy has been a major stumbling block in the 
understanding of the intricacies of metastatic growth. Understanding of the signaling 
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 pathways inducing tumorigenic quiescence may provide important information for preventing 
disease relapse in a large number of cancer patients.   
Currently, very little is known about the mechanism of these dormant cells. Recently, a 
novel endoplasmic reticulum protein ERp29 was found that it was highly expressed in 
dormant breast cancer cell lines while down-regulated in highly-proliferative breast cancer 
cell lines. Moreover, overexpression of ERp29 in the MDA-MB-231 breast cancer cell line 
leads to G0/G1 cell cycle arrest and decreased apoptosis (39). However, the mechanism 
underlying these phenomena is not fully understood. In this thesis project, the aim is to 
explore the molecular mechanisms underlying the ERp29-mediated dormancy characteristics 
in breast cancer. In the ERp29-induced dormant cells, the basal level of the key transcription 
factor eIF2α is found to be down-regulated. The down-regulation of eIF2α in turn promotes 
cyclinD1 translocation to the cytoplasm for degradation. Moreover, down-regulation of eIF2α 
up-regulates CDK inhibitors p21, p27 and p15 to induce cell cycle arrest in the G0/G1 phase. 
On the other hand, the increased expression of ERp29 also down-regulates another 
transcription factor, Nrf2, which functions downstream of PERK and regulates ER and 
oxidative stress signaling. In cancer cells, activation of Nrf2 is reported to facilitate protein 
degradation (49) during the unfolded protein response(UPR) and therefore in ERp29-induced 
dormant cells, the down-regulation of Nrf2 may be an indication of decreased protein 
synthesis as part of the dormancy-induced energy conservation measure. Please refer to 







Figure 19 Schematics showing the molecular players involved in 
ERp29-induced signaling for tumor dormancy. Recently in our lab, we found 
that ERp29 is down-regulatled in breast carcinoma. It negatively regulates cell 
proliferation in breast cancer cells. In a dormant cell line, MCF7, ERp29 is 
extensively expressed. But the mechanism underlying these phenomena is not 
fully understood. Hereby in this thesis, we have explored the molecular 
mechanism of ERp29-mediated cell cycle arrest in breast cancer. In the 
ERp29-induced dormant cells, the basal level of key transcription factor eIF2α is 
down regulated. The down-regulation of eIF2α promotes cyclinD1’s translocation 
to the cytoplasm for degradation. Moreover, down-regulation of eIF2α 
up-regulates CDK inhibitors p27,p21and p15 to induce cell cycle arrest in the 
G0/G1 phase. On the other hand, the increased expression also down-regulates 
another transcription factor, Nrf2, which functions downstream of PERK and 
regulates ER and oxidative stress signaling. In cancer cells, activation of Nrf2 is 
reported to facilitate protein degradation during the unfolded protein response and 
therefore In a ERp29-induced dormant cell, Nrf2 is down-regulated. ERp29 
overexpression also up-regulates molecular chaperone p58ipk,which functions to 
inhibit PERK and the phosphorylation of eIF2α. Phosphorylation of eIF2α 
up-regulates transcription factor ATF4 and ER chaperone BiP.  
  It is well known that ER stress signaling is involved in the induction of tumor cell 
dormancy (50). In the current study, the role of ER stress signaling in ERp29-mediated cell 
cycle arrest was investigated, leading to breast cancer cell dormancy. eIF2α is a key molecule 
known to be involved in ER stress signaling (43). The PERK-eIF2α axis is activated during 
stressful conditions to facilitate tumor cell survival and dormancy. Activation of eIF2α by 
phosphorylation shuts down general protein translation to relieve ER stress and to promote 
cell survival (26).  
Interestingly, the results show that ERp29 down-regulates basal eIF2α expression rather 
than regulating eIF2α phosphorylation. It is thus possible that down-regulation of eIF2α 
reduces global protein synthesis, thereby diminishing the ER stress in breast cancer cells and 
favoring cell survival and dormancy. 
Cell growth arrest and cell survival are two main hallmarks of tumor cell dormancy (50). 
In the current study, it is observed that the cell cycle mediators cyclinD1 and cyclinD2, which 
act downsteam of eIF2α, are down-regulated to induce cell cycle arrest in the G0/G1 phase. 
Meanwhile, the cyclin-dependent kinase inhibitors, p15, p21 and p27 are up-regulated to 
suppress cell cycle progression.  
Tumor cells entering a state of dormancy will require adequate survival signals in order 
to cope with hash conditions such as hypoxia, nutrient deprivation and acidosis. In the current 
investigation, it is found that survival signals in ER stress signaling were activated to 
maintain cell survival in dormant breast cancer cells. A putative ER chaperone, p58ipk was 
up-regulated in ERp29 -induced dormant cells and was down-regulated in ERp29-silenced 
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 MCF7 cells. p58IPK was originally identified as a cellular inhibitor of the interferon-induced 
serine/threonine protein kinase (PKR) which is recruited by the influenza virus to inhibit 
PKR function in eIF2α phosphorylation through a direct interaction with PKR. The 
down-regulation of p58ipk in ERp29-silenced MCF7 cells induces increased expression of the 
transcription factor ATF4 and the ER chaperone BIP. Studies have revealed that BIP can serve 
as a survival signal and its upregulation mediates stress resistance to restore ER homeostasis. 
The up-regulation of BIP and PERK signaling may serve as survival signals that protect 
dormant tumor cells from hash microenvironment conditions and chemotherapeutic stress 
(24).  
Resistance towards apoptosis or programmed cell death is a key factor for the survival of 
a malignant cell. Therefore, it is very important for dormant tumor cells to acquire such a 
resistance. In this research project, p58ipk was focused on it as a possible mediator for 
apoptotic resistance in ERp29-induced dormant cells. A recent study had demonstrated that 
p58IPK can interact with and inhibit PERK phosphorylation, leading to a decreased 
phosphorylation of eIF2α (51). In the ERp29-induced dormant cells, silencing of p58IPK 
stimulated eIF2α phosphorylation and activated the expression of ATF4/CHOP and cleavage 
of caspase-3, leading to an increased cell apoptosis. This was further supported by the early 
studies that eIF2α phosphorylation mediated stress-induced apoptosis (48). Therefore, 
up-regulation of p58IPK may facilitate cell survival under stress in the ERp29-induced 
dormant cells by repressing eIF2α phosphorylation. It is well known that GADD34, a 
downstream target of the activated p-eIF2α, also inhibits eIF2α phosphorylation by a 
feedback loop. These studies provide a clue that induction of p58IPK by ERp29 may help to 
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 protect cells from ER stress by de-phosphorylating eIF2α. Activation of p-eIF2α/ATF4/CHOP 
pro-apoptotic pathway by silencing p58IPK correlated to the increased sensitivity of dormant 
cells to doxorubicin treatment (private communication, manuscript submitted). Collectively, 
all the data indicate that p58IPK is an important coordinator in modulating the crosstalk 
between the ERp29-mediated ER stress and ER-dependent pro-apoptotic signaling by 
inhibiting eIF2α phosphorylation in the ERp29-induced dormant cells. Thus far, we have 
demonstrated that ERp29 regulates cell cycle mediators 
    It has been demonstrated that ERp29 regulates cell cycle mediators expression to induce 
cell cycle arrest. In addition, it has been also shown that ERp29 up-regulates survival signals 
to protect dormant cancer cell from apoptosis. Taken together, these results indicate that 
ERp29 expression favors tumor cell dormancy. However, contradictory results also exist. In a 
study done by Mkrtchian et al., ERp29 expression was associated with larger and more 
malignant phenotype of xenografts in vivo using MCF7 breast cancer cells as a model (38). In 
their study, three different MCF7 stable transfectants were established: mock-transfected cells, 
cells overexpressing wild-type ERp29 and a dominant-negative mutant form of ERp29. These 
transfectants grew at similar rates in vitro. However, when injected with fibroblasts in vivo, 
the wild type ERp29-overexpressing cells grew significantly larger xenografts and formed 
more aggressive tumors than the mouse model injected with cells overexpressing the 
dominant-negative ERp29. As such, they hypothesized that ERp29 might be involved in 
cancer cell interaction with their microenvironment. This hypothesis was supported by the 
fact that endogenous ERp29 was upregulated in the xenografts. Thus they concluded that 
expression of ERp29 correlates with more aggressive phenotype and may have an oncogenic 
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 function.  
Results in the current study showed that ERp29 down-regulates Nrf2. Nrf2 is reported to 
be a direct PERK substrate and that the PERK-dependent activation of Nrf2 is critical for 
survival signaling (51). However, in ERp29-induced dormant cells, an up-regulation of Nrf2 
as a survival response was not observed. On the contrary, Nrf2 was down-regulated in 
ERp29-induced dormant cells. This may be due to a different function of Nrf2 in these 
dormant cells. For example, it has been reported that Nrf2 may play a role in protein 
degradation (49). Therefore, in the dormant cells in which protein synthesis was shut down, 
Nrf2 may be down-regulated to reduce the energy cost for cell survival.  
The study of cancer cell dormancy may lead to the discovery of therapeutic targets to 
prevent cancer relapse. For instance, a cell adherent molecule, β1-integrin(Intβ1), was 
shown to play an important role to induce metastatic growth and resistance to chemotherapy / 
radiation in the dormant cells (52). The inhibitor of this molecule is already under clinical 
trial to maintain the tumor cells in quiescence. Here in this dissertation, we have discussed 
the molecular mechanism of a novel endoplasmic protein, ERp29 in inducing cancer cell 
dormancy. It will be meaningful to research further, for example, how enhancing ERp29 
expression in vivo will prevent cancer relapse.  
FUTURE WORKS 
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The PERK/eIF2α/ATF4 module of ER stress signaling is demonstrated to confer survival 
advantage for tumor growth under hypoxia (17). However, whether this module controls the 
ERp29-mediated cell dormancy studied in this thesis is not yet fully worked out. It has been 
 
 shown that ERp29 up-regulates the expression of PERK and down-regulates the expression 
of eIF2α, but the activation of PERK through its phosphorylation was not studied in the 
current research. It would be worthwhile to examine whether PERK is activated and involved 
in phosphorylation of eIF2α. 
The work thus far has shown that Nrf2 is down-regulated by ERp29 in ERp29-induced 
dormant cells. However, whether Nrf2 is activated or translocated to the nucleus is not clear. 
The phosphorylation of Nrf2 promotes Nrf2 dissociation from Keap1 as well as its nuclear 
translocation. Thus, even though the amount of Nrf2 is decreased, the extent of its activation 
should also be investigated in relation to the ERp29 level.  
On the other hand, it is also necessary to examine the downstream effect of the cell cycle 
regulatory mechanism to further explore how ERp29 regulates cell cycle arrest at G0/G1 
phase. Though several G1 cyclins, CDKs and CDK inhibitors were examined, it is 
meaningful to investigate other G0/G1 cell cycle arrest regulators. For example, it is unclear 
whether the phosphorylated form of Retinoblastoma (Rb) protein and transcriptional factor 
E2F are regulated by an increased level of ERp29 during cancer cell dormancy.  
  Previous results had shown that xenografts with ERp29 transfection forms less 
proliferative tumors in vivo, but as to how one could kill these dormant cells remains 
unsolved. In the future, it is important to attempt to remove these dormant cells by targeting 
the ERp29-regulated ER stress signal pathway. To fulfill this task, it is necessary to confirm 
which part of the ER stress signaling is activated to maintain ERp29–induced tumor cell 
dormancy. So far it has been shown that ERp29 down-regulates eIF2α, a key translation 
49 
 
 initiation factor that controls global protein synthesis, and that ERp29 up-regulates the key 
ER chaperone BIP and the key transcription factor ATF4. To further explore how ER stress 
signaling is involved in ERp29-induced tumor cell dormancy, it is possible to knock down 
BIP and ATF4 to see if the dormancy is perturbed. Briefly, in ERp29-mediated dormant cells, 
BIP or ATF4 can be knocked down by siRNA. The BIP-knocked down or ATF4-knocked 
down cells can then be injected into mouse models, and subsequently their tumorigenic 
activity and sensitivity to chemotherapeutic drugs further investigated. This may enable the 
researchers to determine potential molecular targets for killing off dormant cancer cells and 
thus develop effective therapeutics to prevent cancer relapse. 
 
CONCLUSION 
Cancer cell dormancy is one of the means for tumor cells to survive in harsh conditions and 
resist chemotherapeutic measures targeting their elimination. Studying the mechanism for 
cancer cell dormancy may help in preventing recurrent metastatic disease. Unfortunately, the 
mechanism of cancer cell dormancy is so far poorly understood. Previously, it has been found 
that a novel endoplasmic reticulum protein ERp29 induces cell dormancy in breast cancer. In 
this thesis project, the author tried to elucidate the molecular mechanisms underlying 
ERp29-mediated cancer cell dormancy in breast cancer. 
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The current results demonstrated that ERp29 modulate the ER stress signaling pathway in 
dormant cells. The key translation initiation factor eIF2α is down-regulated to shut down 
global protein synthesis. Meanwhile, one of the important ER chaperones, p58ipk, is 
 
 up-regulated to facilitate cell survival under ER stress, where as the transcription factor Nrf2 
is down-regulated to reduce excess energy cost for protein degradation. In summary, the 
author has provided proof-of-concept evidence that ERp29-mediated cell dormancy is 
induced through regulation of ER stress signaling.  
With the further pursuit of knowledge of the molecular mechanism underlying 
ERp29-mediated cell dormancy, it would be possible to target one or more molecules in 
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APPENDIX 1    
Reagents 
1. Bio-Rad (USA) 
30% acrylamide 
Ammonium persulfate (APS) 
N’, N’, N’, N’-Tetramethylethylenediamide (TEMED) 
 
2. Merck(USA) 
Ethanol(70%)for sterile use 
Methanol(20%)for Western blot transfer buffer 
 
3. Sigma-Aldrich (Steinheim, Germany) 
Phosphatase cocktail inhibitors I and II 
 
4. Pierce (Rockford, IL,USA) 
Coomassie PlusTM Protein Assay Reagent 
SuperSignal West Pico Chemiluminescent Substrate 
 
5. Promega (USA) 
Modified porcine trypsin (Sequencing grade) 
 
6. Roche(Indianapolis, IN,USA) 
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 Complete, EDTA-free protease inhibitor cocktail tablets 
 
7. USB Coporation (USA) 
Dithiotreitol (DTT) 
Glycine 




8. Invitrogen (Eugene, OR, USA). 
Geneticin sulphate (G418) 
Fetal bovine serum  
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Endoplasmic reticulum protein 29 (ERp29) is a novel ER luminal protein and plays a 
critical role in protein unfolding and secretion. However, its function in cancer progression is 
not fully understood. Recently, we reported that ERp29 is a novel tumor suppressor which 
drives the proliferative MDA-MB-231 breast cancer cells into a dormant state. Here, we provide 
evidence that the ERp29-induced cancer cell dormancy was modulated by activation of p38 and 
up-regulation of p58IPK. In this dormant cell model, over-expression of ERp29 significantly 
down-regulates the expression of urokinase receptor (uPAR), 1-integrin and epidermal growth 
factor receptor (EGFR), and highly increases the phosphorylation of p38 and reduces MMP-9 
secretion. Blockage of p38 phosphorylation by pharmacological inhibitor significantly 
down-regulates the expression of basal eukaryotic translation initiation factor 2α (eIF2α) and 
cyclin D2 and up-regulates the expression of cyclin-dependent kinase inhibitors (p15 and p21). 
Further, we show that p58IPK was markedly increased to inhibit eIF2α phosphorylation. 
Reduction of p58IPK by RNA interference stimulated eIF2α phosphorylation and increased the 
expression of eIF2α phosphorylation-dependent activating transcription factor 4 (ATF4) and 
growth arrest and DNA damage-inducible protein (GADD153/CHOP) and the activation of 
caspase-3, leading to enhanced cell apoptosis and sensitivity to doxorubicin. Our studies indicate 
that activated p38 regulates the expression of checkpoint molecules to induce G1 arrest while the 
up-regulated p58IPK inhibits eIF2α phosphorylation to relieve excessive ER stress, coordinately 
modulating the ERp29-induced cell dormancy and survival. Our findings suggest a novel 
regulatory mechanism of ERp29-induced cancer cell dormancy in breast cancer. 
 
Breast tumor cell dormancy is a significant clinical problem in cancer treatment. Most of the 
dormant cells do not express proliferation markers and are resistant to conventional therapies that 
target actively dividing cells (1). These dormant cells can survive for a long time in blood and/or bone 
marrow and recapitalize a proliferative characteristic to form a local and/or distant metastasis when 
cells are activated under certain condition. Although highly prevalent, little is known about the 
mechanisms responsible for the regulation of dormancy in these cells due to lack of suitable 
experimental models and limited clinical accessibility to the microscopic size of dormant tumors. 
 Currently there is no efficient therapeutic treatment that can keep tumor cells in dormant state for 
extended periods of time and prevent them from localization and proliferation. Therefore, 
understanding the mechanisms of inducing tumor cell dormancy is of clinical importance in 
suppressing tumor cell reactivation and cancer recurrence. This may lead to novel strategies to 
prolong the extent of dormant state to block tumor formation or to enhance signaling pathways that 
stimulate dormant cells into apoptosis or to improve their sensitivity to chemotherapy.      
Tumor dormancy represents the inability of cells to produce tumors or the capability to form 
small nodules after prolonged latency. In general, dormant cells are characterized as cell cycle G0/G1 
arrest or the similar proliferative and apoptotic rates leading to a little overall gain in cell mass (2). 
Several mechanisms have been proposed to explain the tumor dormancy. These include impaired 
angiogenesis by which tumor growth is blocked due to inability to form new and functional blood 
vessels; cellular dormancy by which tumor cells are in quiescent state due to cell cycle arrest, and 
immunosurveillance by which tumor mass growth is blocked by active immune response (3-5). 
Mechanistic studies in human squamous carcinoma cells have shown that urokinase receptor (uPAR2), 
epidermal growth factor receptor (EGFR), extracellular signal-regulated kinase (ERK) and p38 
activities play critical roles in regulating tumor cell dormancy (2, 6, 7). The uPAR is defined to be a 
central regulator of a balance between p38 and ERK activation as down-regulation of uPAR favors 
p38 activation over ERK to induce tumor cell dormancy (8, 9). In addition, activated 
ATF6α-Rheb-mTOR signaling, regulated in part by p38, was found to be essential in maintaining cell 
survival for quiescent but not for proliferative squamous carcinoma cells (10). 
Tumor cell dormancy has also been mechanistically linked with endoplasmic reticulum (ER) 
stress signaling. Accumulation of misfolded/unfolded proteins in the ER lumen results in ER stress 
and subsequently initiates an integrated signal transduction pathway known as Unfolded Protein 
Response (UPR) to ameliorate the protein load on the ER. The UPR is mediated by at least three ER 
proximal sensors, PKR-related ER kinase (PERK), inositol requiring enzyme-1 (IRE-1) and activating 
transcription factor 6 (ATF6) (11, 12). PERK is a serine/threonine kinase that phosphorylates 
eukaryotic translation initiation factor 2α (eIF2α) at Ser51 on stress and consequently attenuates global 
protein translation and induces G0/G1 arrest (13), a characteristic of dormancy of cells. Hence, cells 
may coordinate growth arrest and survival signals by activating ER stress, conferring dormant cells a 
resistance to stress-induced death. The role of p38 activation in inducing tumor cell dormancy by 
regulating PERK/p-eIF2α pathway has been established in human squamous carcinoma cells (14, 15). 
The mechanistic link between ER stress and tumor cell dormancy through p38 activation suggests an 
important role of p38-regulated network in modulating tumor cell quiescence, survival and apoptosis 
(14-16)    
We have established a “dormancy-like” breast cancer cell model by exogenously over-expressing 
ER protein 29 (ERp29) in the high proliferative and invasive MDA-MB-231 cells (17). 
Over-expression of ERp29 in MDA-MB-231 cells results in G0/G1 arrest and significantly drives the 
proliferative cells into a quiescent state in vitro, thus leading to a marked delay in the onset of 
tumorigenesis and formation of small nodule of xenograft tumors in vivo (17). The ERp29-induced 
dormant cells are also characterized by loss of proliferative markers (e.g., fibronectin, uPAR, 
1-integrin, EGFR, Ki-67) and gain of molecules that are involved in cessation of cell growth and 
tumor suppression (e.g., cyclin-dependent kinase inhibitors p15 and p21, E-cadherin) (17). 
Significantly, the established dormant cell model phenotypically resembles that of epithelial MCF-7 
cells (17) and demonstrates high resistance and increased survival to doxorubicin treatment (18). It 
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 was reported that desensitizing doxorubicin is another important clinical characteristic of solitary 
dormant tumor cells (1). Based on the cellular behavior of the ERp29-overexpressed MDA-MB-231 
cells in vitro and in vivo, we have implicated a pivotal role of ERp29 in inducing tumor cell dormancy, 
but the mechanisms remain elusive. Interestingly, we observed that, in addition to stimulating UPR by 
enhancing X-box binding protein 1 (XBP-1) slicing, ERp29 regulates PERK/p-eIF2α pathway by 
significantly reducing the expression of basal eIF2α, but not by increasing its phosphorylation (18). 
This may implicate a different regulatory mechanism of ERp29 in inducing tumor cell dormancy and 
survival. 
In this report, we present evidence that uPAR/1-integrin/EGFR and its downstream focal 
adhesion kinase (FAK) /phosphorylated -ERK (p-ERK) are significantly decreased while p38 is 
highly phosphorylated in the ERp29-induced dormant MDA-MB-231 cells. Activation of p38 
down-regulates cyclin D2 and up-regulates p15 and p21, leading to G0/G1 arrest. Furthermore, we 
show that p38 activation by ERp29 negatively regulates the expression of basal eIF2α, while the 
up-regulated p58IPK inhibits the phosphorylation of eIF2α. Finally, we demonstrate that silencing of 
p58IPK facilitates eIF2α phosphorylation- dependent activation of ATF4/CHOP/caspase-3 
pro-apoptotic signaling, leading to an increased sensitivity to chemotherapeutic treatment and cell 
death. Our results thus demonstrate that p38 activation and up-regulation of p58IPK are central 




Antibodies and reagents – The following antibodies were used in this study: mouse anti-uPAR 
from R&D Systems (Minneapolis, MN), rabbit anti-EGFR (c-term) from Epitomics (Burlingame, CA), 
rabbit anti-ERp29 from Acris (Hiddenhayse, Germany), rabbit anti-PERK, rabbit anti-phospho-PERK 
(Thr980), rabbit anti-p15INK4B, rabbit anti-p21Wafi/Cip1, rabbit anti-β1-integrin, rabbit anti-eIF2α, mouse 
anti-p-eIF2α (Ser51), rabbit anti-p58IPK, rabbit anti-FAK, rabbit anti-p38, mouse anti-GADD153/CHOP, 
rabbit anti-phospho-p38 (Thr180/Tyr182), and rabbit anti-cleaved caspase-3 from Cell Signaling 
Technology (Beverley, MD),  rabbit anti-ATF4 and rabbit anti-Bip/GRP78 from Novus Biologicals 
(Littleton, CO), mouse anti-β-actin from Sigma-Aldrich (St. Louis, MO). SB203580 was purchased 
from Calbiochem (San Diego, CA). Complete, EDTA-free protease inhibitor cocktail tablets were 
purchased from Roche Diagnostics (Indianapolis, IN) and phosphatase cocktail inhibitors I and II 
were from Sigma-Aldrich. Geneticin sulphate (G418) and lipofectamineTM 2000 transfection reagent 
were supplied from Invitrogen (Eugene, OR). 
Cell Culture – MDA-MB-231 and MCF-7 breast cancer cell lines were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA) and maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Invitrogen). 
MDA-MB-231 cells transfected with pcDNA/ERp29 or pcDNA, and MCF-7 cells transfected with 
shRNA/ERp29 or control shRNA were generated as previously described (17). All the transfected 
cells were maintained in DMEM supplemented with 10% FBS and G418 (Invitrogen, 2 mg/ml for 
MDA-MB-231 transfectants, 1 mg/ml for MCF-7 transfectants). Cells were cultured at 370C with 5% 
CO2 in a humidified incubator. 
Immunofluorescence and Confocal Microscopy – Immunofluorescent analysis was performed as 
described earlier (17, 18). Briefly, cells plated on coverslips were fixed with 4% paraformaldehyde 
(Sigma-Aldrich) for 20min and permeabilized with 0.1% Triton X-100 for 10min. The cells were then 
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 incubated overnight with primary antibodies against Ets-1 or cyclin D2 at 40C, followed by incubation 
with Alexa Fluor 488-conjugate streptavidin (1:1000, Invitrogen) for 1h at room temperature. After 
final washes with PBS, the coverslips were mounted using the antifade mounting fluid containing 
DAPI and the images were examined and captured using Olympus Fluoview FV500 confocal laser 
scanning microscope (Olympus, Japan). Raw images were analyzed using Olympus FV10-ASW 1.7 
Viewer software (Olympus). 
Treatment with pharmacological inhibitor – Cells were equally seeded in each well (~5×105/per 
well) of 6-well plates and incubated at 370C in CO2 incubator. When cells reached ~90% confluence, 
these cells were treated with SB203580 (final conc. 40µM) or dimethyl sulfoxide (DMSO) as 
previously described (19). After 24h post-treatment, cells were collected and the total proteins were 
extracted for Western blot analysis.  
RNA Interference and Transfection – Small interfering RNAs (siRNAs) against p58IPK (Cell 
Signaling Technology) and control siRNA (Santa Cruz Biotechnology) were used for gene 
knockdown according to the procedures as previously described (18). Cells at 60-80% confluence 
were transfected with siRNA at a final concentration of 100nM of the respective siRNA using 
LipofectamineTM 2000 transfection reagent (Invitrogen) according to the manufacturer’s instructions. 
Twenty four or 48 h after transfection, cells were harvested for Western blot analysis. 
Cell Viability assay – Cell viability was analyzed with a 3-(4-5-dimethylthiazol-2-yl)-5- 
(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) assay kit (Promega 
Corporation, Madison, WI) according to the manufacturer’s instruction. Briefly, cells (5×105 cells/per 
well) were seeded in each well of 6-well plates. Cells at 60-80% confluence were treated with 
p58IPK/siRNA or control siRNA for 24h and cell viability was assessed. Alternatively, abovementioned 
siRNA-treated cells were further treated with doxorubicin (final conc. 200µg/ml) or DMSO for 24h 
and cell viability was analyzed as followed. Cells were incubated with MTS solution for 4h and the 
absorbance of formazon at 492nm was measured with Infinite F200 microplate reader (TECAN 
Austria GmbH, Grodig, Austria). The absorbance of cells treated with scramble siRNA was defined as 
100% survival (control), and the remaining data were converted to a percentage of the control.  
Western Blot Analysis – Western blotting was performed by standard protocol as previously 
described (17). Briefly, cell lysates were extracted with RIPA Buffer (1% Igepal, 1% sodium 
deoxycholate, 0.15M sodium chloride, 0.01M sodium sulphate, pH 7.2 and 2mM EDTA), 
supplemented with protease inhibitors (Roche Diagnostics) and phosphatase cocktail inhibitors I and 
II (1:100, Sigma-Aldrich).  Cell lysates were centrifuged at 13,000×g for 20min at 40C and 
protein-containing supernatant was collected. The total proteins (30-50µg) were separated by 10% 
SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked with 5% skim milk for 
1h at room temperature and probed with the indicated primary antibodies. Goat-anti-mouse 
horseradish peroxidase (HRP) (Upstate Biotechnology, Lake Placid, NY) or goat-anti-rabbit HRP 
secondary antibody (ZyMED Laboratories Inc, San Francisco, CA) were used as secondary antibody. 
The chemiluminescent signal was developed with Supersignal® West Pico Chemiluminescent 
substrate (Pierce, Rockford, IL). Signal intensity was analyzed using the GeneTools software 
(Syngene, Frederick, MD). The level of -actin was used as a loading control. 
Zymography – Cells at 50-60% confluence were washed twice with sterilized PBS buffer (pH 
7.4) and then incubated with serum-free DMEM for 48 h. The conditioned medium was collected and 
centrifuged at 3000×g for 15min at 40C to remove cell debris. The supernatant was concentrated 
80-100-fold using Biomax Ultrafree Centrifugal Filter Unit (Millipore, Bedford, MA) with a 10kDa 
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 pore diameter cutoff. The total secreted proteins (30-50µg) were mixed with SDS sample buffer in the 
absence of reducing reagents and resolved in 7.5% polyacrylamide gels containing 0.1% gelatin under 
nonreducing conditions. MMP activity was assessed by gelatin zymography. Briefly, the gels were 
washed for 1h at room temperature with 50mM Tris-HCl buffer (pH 7.5) containing 2.5% Triton 
X-100 and 5mM CaCl2 and then washed extensively with Milli-Q water. After removing SDS, the 
gels were further incubated overnight at 37°C in digestion buffer (50mM Tris, pH 7.5, 5mM CaCl2, 
0.1mM ZnCl, 150mM NaCl) to allow proteolysis of the gelatin substrate, followed by staining with 
5% Coomassie Brillient Blue R-250 and de-staining in methanol/acetic acid/water (10:10:80). The 
gelatinolytic activities were detected as clear bands against blue background. 
Statistical Analyses – Student’s t test was used to analyze the significance of differences. 
Two-tailed p<0.05 was considered as significant. All cell culture experiments were performed in 




Over-expression of ERp29 induces cell dormancy through down-regulation of 
uPAR/1-Integrin/EGFR – We reported that over-expression of ERp29 in MDA-MB-231 cells resulted 
in cell growth arrest and drove proliferative cells into a dormant state (17). Mechanistic study 
revealed a transcriptional down-regulation of uPAR, β1-integrin and EGFR in the ERp29-induced 
dormant MDA-MB-231 cells (17). Immunoblotting analysis further demonstrated a significant 
decrease of protein expression of uPAR/β1-integrin/EGFR complex in these dormant cells (clone B 
and E) (Fig.1A, left panel). uPAR is an important membrane receptor in regulating both cell growth 
and invasion (20, 21). Its expression is highly regulated by v-ets erythroblastosis virus E26 oncogene 
homolog 1 (Ets-1) in invasive breast cancer (22). We showed that Ets-1 was down-regulated by 
ERp29 (Fig.1A, right panel), further supporting a mechanistic link of ERp29 in attenuating uPAR in 
these dormant cells. Immunofluorescent analysis indicated that Ets-1 was expressed in both nucleus 
and cytoplasm in the control cells and over-expression of ERp29 resulted in a significant reduction of 
Ets-1 in these dormant cells (Suppl. Fig. 1A). Given that activation or loss of this complex decides the 
cell destination between proliferation and dormancy, we further investigated whether ERp29-mediated 
cell growth arrest and dormancy in MDA-MB-231 cells was associated with the interruption of 
downstream signaling regulated by this complex.  
Over-expression of ERp29 activates p38 phosphorylation and decreases FAK expression and 
MMP-9 secretion – Two important signaling pathways under this complex include FAK/p-ERK and 
cell division cycle 42 (Cdc42)/phosphorylated-p38 (p-p38) (3). Activation of FAK/p-ERK facilitates 
cell proliferation and tumorigenesis whereas activation of Cdc42/p-p38 promotes cell dormancy and 
G1 arrest. In addition to inhibition of p-ERK in the ERp29-induced dormant MDA-MB-231 cells (17), 
here we showed that expression of FAK was highly reduced in the ERp29-induced dormant cells 
comparing to the proliferative MDA-MB-231 cells (Fig. 1B, left panel), while knockdown of ERp29 
in MCF-7 cells enhanced the expression of FAK (Fig.1B, right panel). Inhibition of FAK was found to 
induce cell dormancy in human carcinoma cells (23). Accompanying with the inhibition of FAK in the 
dormant cells, the level of p-p38 was significantly enhanced, although the expression of basal p38 was 
highly decreased (Fig. 1B, left panel). The ERp29-enhanced phosphorylation of p38 was further 
verified in MCF-7 cells where knockdown of ERp29 resulted in a reduction of p-p38 (Fig. 1B, right 
panel). Clearly, these findings indicate that over-expression of ERp29 in MDA-MB-231 cells 
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 markedly induces p38 phosphorylation and decreases FAK expression, leading to a signaling balance 
that favors p38 over ERK activity to induce a dormant state.  
It has been reported that matrix metalloproteinases (MMPs) are the important downstream 
molecules regulated by uPAR/β1-integrin, p38 and ERK signaling and have critical role in matrix 
degradation and cell invasion (24, 25). To determine whether the reduced expression of 
uPAR/β1-integrin and activated p38 in the ERp29-induced dormant cells result in loss of MMP 
activity, both the vector-transfected control cells and the dormant cells (clone B as an example) were 
serum starved for 48h and the secretion of MMPs was assessed using gelatin zymography. As shown 
in Figure 1C, the dormant cells (clone B) showed a significantly decreased (~5.4 fold) secretion of 
MMP-9 based on the intensity of negatively stained band. However, the secretion of MMP-2 was not 
affected. These results further support a less invasive capacity of ERp29-induced dormant cells (17). 
p38 activation induces G1 arrest through up-regulating cyclin-dependent kinase inhibitors p15 
and p21 and down-regulating cyclin D2 – To further establish the molecular changes in the 
ERp29-induced dormant cells, the expression of cyclin D1/D2 and cyclin-dependent kinase inhibitors 
p15 and p21 was examined. Consistent with our early report that transcription of cyclin D2 was highly 
inhibited by ERp29 (17), we demonstrate that protein expression of cyclin D2 was significantly 
decreased whereas cyclin D1 was only slightly reduced in the ERp29-induced dormant cells compared 
to the proliferative mock-transfected control cells (Fig.2 A, left panel). Further, immunofluorescent 
analysis revealed that cyclin D2 was highly reduced in the nucleus and aggregated to form particles in 
the cytoplasm, indicating a translocation and aggregation of cyclin D2 in cytoplasm in the 
ERp29-induced dormant cells (Suppl. Fig. 1B).  On the other hand, knockdown of ERp29 in MCF-7 
cells resulted in an up-regulation of cyclin D2, with no effect on cyclin D1 (Fig. 2A, right panel). 
Subsequently we investigated the role of ERp29 in regulating the expression of p15 and p21 which 
were transcriptionally up-regulated by ERp29 (17). As indicated in Figure 2A, both p15 and p21 were 
highly expressed in these dormant cells, and knockdown of ERp29 in MCF-7 cells led to a great 
reduction of p15 and moderate decrease of p21. These results further substantiate the molecular 
mechanism underlying the ERp29-induced G0/G1 arrest in the dormant cells. 
It was reported that p38 activation resulted in inhibition of cyclin D1/D2 in the dormant D-HEp3 
cells (8). To further establish whether the enhanced p38 phosphorylation is involved in the 
ERp29-mediated up-regulation of p15 and down-regulation of cyclin D2 in the ERp29-induced 
dormant cells, these cells (clone B cells were used as a model) were treated with 40µM of SB203580, 
a specific inhibitor of p38 phosphorylation (18, 19, 26). After 24h post-treatment, the cells were 
harvested and the level of protein expression was assessed by Western blotting. As shown in Figure 
2B, concurrent with a significant reduction of p38 phosphorylation, the expression of p15 was highly 
decreased while that of cyclin D2 was markedly increased in the inhibitor-treated dormant cells, 
compared to the cells treated with DMSO. Clearly, these results indicate that p38 phosphorylation is 
critical in modulating the expression of these checkpoint proteins in the ERp29-induced G1 arrest 
cells.      .   
Activation of p38 inhibits basal eIF2α expression and enhances eIF2α phosphorylation – It has 
been demonstrated that activated p38 functionally links the ER stress signaling in modulating cell 
dormancy, survival and apoptosis (15). Moreover, activation of eIF2α by phosphorylation induces G1 
arrest and cell survival by blocking cyclin D1/D2 translation/stability (13). However, previous studies 
revealed that over-expression of ERp29 highly inhibited the expression of basal eIF2α, while the 
eIF2α phosphorylation was not markedly changed (18, Fig. 3A, left panel). This is further supported 
64 
 
 by the notion that knockdown of ERp29 in MCF-7 cells increased the expression of basal eIF2 (Fig. 
3A, right panel). These data demonstrate a significant role of ERp29 in negatively regulating the 
expression of basal eIF2α in our dormant cell models. Interestingly, reduction of ERp29 also increase 
the level of p-eIF2α and the relative phosphorylation of eIF2α was moderately enhanced (~1.76-fold 
increase) (Fig. 3A, right panel), implicating an activation of PERK/p-eIF2α when ERp29 was reduced 
in MCF-7 cells (Fig. 3A, right panel). In other words, ERp29 expression attenuates activation of 
PERK/ p-eIF2α pathway. 
Since p38 phosphorylation suppresses cyclin D2 and increases p15 in the ERp29-induced 
dormant cells (Fig. 2B), we propose that p38 phosphorylation might affect the basal eIF2α expression. 
To address this possibility, p38 phosphorylation was blocked with inhibitor SB203580 in the dormant 
cells (clone B). As shown in Figure 3B, when p38 activation was highly reduced in these cells, the 
expression of basal eIF2α was markedly increased (~3.4-fold), while the relative phosphorylation of 
eIF2α was significantly reduced when compared to the cells treated with DMSO (0.24 vs 1.0, 4.2-fold 
decrease) (Fig.3B, left panel). Similar scenarios were also observed in MCF-7 cells treated with this 
inhibitor: reduction of p38 phosphorylation led to 2-fold increase of basal eIF2α and approximately 
6.5-fold reduction of eIF2α phosphorylation compared to the cells treated with DMSO (Fig. 3B, right 
panel). These data suggest that p38 phosphorylation negatively regulates the expression of basal 
eIF2α, but positively regulates eIF2α phosphorylation.  
However an important observation is that highly activated p38 in the ERp29-induced dormant 
cells (Fig.1B, left panel) was unable to increase eIF2α phosphorylation (18, Fig.3 A, left panel). 
Furthermore, reduction of p-p38 (Fig.1B, right panel) in the ERp29-knockdown MCF-7 cells was 
unable to decrease the relative phosphorylation of eIF2α. Instead, relative phosphorylation of eIF2α 
was moderately increased (Fig. 3A, right panel). Considering these apparently contradictory notions, 
we propose that other factors that functionally counteract eIF2α phosphorylation by p-p38 might be 
concomitantly regulated by ERp29 and are responsible for the inhibition of eIF2α phosphorylation in 
the ERp29-induced dormant cells.  
ERp29-mediated up-regulation of p58IPK inhibits phosphorylation of eIF2α – Our previous 
studies demonstrated that over-expression of ERp29 in MDA-MB-231 cells led to activation of 
XBP-1 (18). One of the ER proteins that are specifically regulated by XBP-1 is p58IPK (27). p58IPK, an 
inhibitor of protein kinase, can directly bind to PERK to inhibit PERK phosphorylation, resulting in 
inhibition of eIF2α phosphorylation (28, 29). We then examined the expression of p58IPK in the 
dormant cells and investigated its role in regulating eIF2α phosphorylation. As shown in Figure 4A, 
p58IPK was markedly up-regulated (2.84-fold) in the ERp29-induced dormant cells (clone B), and 
knockdown of ERp29 in MCF-7 cells highly reduced its expression. Significantly, when the 
up-regulated p58IPK was silenced with siRNA in the dormant cells (clone B), phosphorylation of eIF2α 
was restored (3.2-fold increase) without highly affecting the expression of basal eIF2α (Fig. 4B, left 
panel). Similar results were also observed in MCF-7 cells in which silencing of p58IPK markedly 
stimulated eIF2α phosphorylation by 2.56-fold increase (Fig. 4B, right panel). These results suggest 
that the up-regulated p58IPK plays a critical role in inhibiting eIF2α phosphorylation in the 
ERp29-induced dormant cells. 
In addition to p58IPK, we also observed that expression of basal PERK was highly increased 
whereas phosphorylation of PERK was weakly detectable in these dormant cells (clone B) as 
compared to the control cells (Fig. 4C, left panel). It is reasonable that inactivation of PERK is mostly 
due to the increased level of p58IPK which binds to PERK and represses PERK phosphorylation (29). 
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 Over-expression of ERp29 increased the expression of Bip/GRP78 in the dormant cells (Fig. 4C, 
middle panel). However, knockdown of ERp29 in MCF-7 cells also resulted in an increase of 
Bip/GRP78 (Fig. 4C, right panel). Clearly, there is no direct mechanistic link between these two 
molecules. Furthermore, expression of eIF2α phosphorylation-dependent transcription factors ATF4 
was not changed in the ERp29-induced dormant cells (Fig. 4C, middle panel). In contrast, knockdown 
of ERp29 in MCF-7 cells activated the expression of ATF4 (Fig. 4C, right panel), consistent with the 
enhanced eIF2α phosphorylation in the ERp29-knockdown MCF-7 cells (Fig. 3A, right panel). These 
results indicate that the ER-dependent pro-apoptotic signaling is markedly suppressed by ERp29 in 
these dormant cells.  
Silencing of p58IPK activates p-eIF2α/ATF4/CHOP pathway in the ERp29-induced dormant cells 
– The aforementioned data demonstrated that over-expression of ERp29 up-regulates p58IPK, leading 
to inhibition of eIF2α phosphorylation. Given that silencing of p58IPK in the ERp29-induced dormant 
cells re-activates phosphorylation of eIF2α (Fig. 4B, left panel), reduction of p58IPK might be 
responsible for activation of eIF2α phosphorylation-dependent ATF4/CHOP pro-apoptotic pathway. 
As expected, silencing of p58IPK in dormant cells (clone B) led to a significant increase of both ATF4 
and CHOP expression (Fig. 5A, left panel). Consistently, similar results were also achieved in MCF-7 
cells in which silencing of p58IPK greatly increased the expression of ATF4 and CHOP (Fig. 5A, right 
panel). In consistent with previous studies that p58IPK over-expression decreased eIF2α 
phosphorylation-dependent expression of ATF4/CHOP (28), our data further demonstrate that p58IPK 
is a key regulator of the p-eIF2α/ATF4/CHOP pathway and its up-regulation is crucial in maintaining 
the ERp29-induced cell survival.  
Silencing p58IPK interrupts dormancy and induces cell apoptosis – Previous studies have shown 
that over-expression of ERp29 in the ERp29-induced dormant cells markedly increased the resistance 
to doxorubicin while knock-down of ERp29 in MCF-7 cells sensitized to it (18). Furthermore, the 
above data demonstrate an important role of p58IPK in inhibiting eIF2α phosphorylation and 
pro-apoptotic signaling in these dormant cell models. We next examined if the up-regulated p58IPK 
plays a critical role in the ERp29-mediated cell survival and drug resistance.  
To determine whether silencing p58IPK results in sensitivity to doxorubicin and causes cell death, 
the ERp29-induced dormant cells and MCF-7 cells were respectively treated with p58IPK siRNA or 
scramble control siRNA for 24h, followed by 24h treatment with doxorubicin (200ng/ml). The 
viability of these treated cells was examined. As indicated in Figure 5A, the dormant cells (clone B) 
and MCF-7 cells treated with p58IPK siRNA showed an enhanced expression of cleaved caspase-3, 
indicating an activation of cell apoptosis after p58IPK silencing. Further studies showed that these 
p58IPK siRNA-treated cells had a highly decreased cell viability compared to the cells treated with 
control siRNA (Fig. 5B, column 3 vs 1; column 7 vs 5). When these siRNA-treated cells including 
those treated with control siRNA were further exposed to doxorubicin, the dormant cells pre-treated 
with p58IPK siRNA showed a 3.0-fold reduction of cell viability over the dormant cells pre-treated 
with control siRNA (column 4 vs 2), suggesting that silencing of p58IPK significantly sensitized these 
dormant cells to this drug. A similar effect was also observed in MCF-7 cells where repression of 
p58IPK enhanced the cytotoxicity to doxorubicin, leading to approximately 2.5-fold decrease of viable 
cells compared to the cells pre-treated with control siRNA (Fig. 5B, column 8 vs 6). As a result, 
silencing of p58IPK in the ERp29-induced dormant cells disrupts the dormant state and increases cell 






Tumor cell dormancy is a critical step for tumor cells to escape from radiotherapeutic and 
chemotherapeutic treatment in cancer patients. It is therefore clinically important to understand the 
mechanisms underlying tumor cell dormancy to prevent cancer recurrence. In the present study, we 
demonstrated that ERp29 is one of the potential factors driving proliferative tumor cells into 
dormancy in breast cancer. In the ERp29-induced dormant cell model, we provide evidence that 
over-expression of ERp29 significantly reduced the expression of uPAR, 1-integrin and EGFR, the 
essential players in the decision between tumor cell proliferation and dormancy (7). Reduction of this 
complex leads to attenuation of FAK/p-ERK and activation of p38 and consequently propels tumor 
cells into quiescence by down-regulating eIF2α expression, reducing cyclin D2 and increasing p15 and 
p21. Importantly, we demonstrate that the up-regulated p58IPK in the dormant cells plays a critical role 
in attenuating eIF2α phosphorylation and inhibiting ATF4/CHOP/Caspase-3 pro-apoptotic pathway, 
leading to an enhanced cell survival.  
The role of uPAR/1-integrin/EGFR complex and its downsteam molecules (e.g., FAK and p38) 
in modulating tumor cell dormancy has been well described in dormant squamous tumor cell models 
(2, 8, 9, 16, 23). The current studies in our established ERp29-induced dormant cells further support 
the significance of loss of the uPAR/1-integrin /EGFR complex in tumor cell dormancy by activating 
p38 phosphorylation and down-regulating FAK. Phosphorylation of p38 due to the loss of this 
complex has been demonstrated to be a central regulator in regulating cell dormancy, survival and 
apoptosis (3, 30). A significant link of p38 phosphorylation with cell cycle arrest at G0/G1 phase and 
cell survival via ER stress was mechanistically established by the fact that activation of p38 enhanced 
PERK/p-eIF2α signaling by stimulating phosphorylation of eIF2α (14), leading to induction of G0/G1 
arrest by down-regulating cyclin D1 (12, 13). Interestingly, in our established ERp29-induced dormant 
cell models, the expression of basal eIF2α was highly inhibited without highly affecting its 
phosphorylation (Fig. 3A, left panel). In addition, the expression of cyclin D2, but not D1, was highly 
decreased (Fig. 2A), and the cyclin-dependent kinase inhibitors p15 and p21 were markedly increased 
(Fig. 2A). These data may reveal a novel mechanism of ERp29 in driving proliferative cells into G1 
arrest and cell dormancy.  
We demonstrate a critical role of p38 phosphorylation in the ERp29-mediated G1 arrest. This is 
reflected by the fact that inhibition of p38 phosphorylation by pharmacological inhibitor in the 
ERp29-induced dormant cells reversed the expression of cyclin D2 and inhibited the expression of p15 
(Fig. 2B). Meanwhile, we also demonstrate that inhibition of p38 phosphorylation restored the level of 
basal eIF2α (Fig. 3B), indicating the importance of p38 phosphorylation in negatively regulating the 
basal eIF2α expression in the ERp29-induced dormant cells. C-JUN/AP-1 is one of the transcription 
factors regulating eIF2α expression (31). Transcription factor profile analysis revealed that 
c-JUN/AP-1 is one of the key transcription factors that are negatively regulated by p38 
phosphorylation (16, 32). It was found to be reduced in dormant D-HEp3 cells (16) and similarly in 
the ERp29-induced dormant tumor cells (17). The ERp29-mediated down-regulation of basal eIF2α is 
mostly due to the inhibition of c-Jun via activation of p38. Collectively, the ERp29-mediated 
activation of p38 negatively regulates eIF2α expression. 
ER stress signaling is an important determinant in deciding cell dormancy, survival and 
autophagy (11, 15, 33). Over-expression of ERp29 in the ERp29-induced dormant cells leads to 





enhanced phosphorylation of eIF2α, a mechanism leading to attenuation of general protein synthesis 
and activation of ATF4/CHOP under ER stress (34), over-expression of ERp29 is unable to increase 
eIF2α phosphorylation (18, Fig. 3A), although p38 is highly activated (Fig. 1B) and PERK is highly 
expressed (Fig. 4C) in the ERp29-induced dormant cells. PERK is one of the specific kinases that 
phosphorylate eIF2α (13). Activation of PERK induces cell survival in response to ER stress (35) and 
suppresses autophagy and lysosomal dysfunction (36). In the ERp29-induced dormant cells, 
expression of the key regulators including p-p38 and PERK are significantly increased, while eIF2α 
phosphorylation is not further improved. This may implicate that dephosphorylation of eIF2α that 
counteracts the phosphorylation exerted by its upstream kinases is concomitantly stimulated in the 
ERp29-induced dormant cells. 
We reported that p58IPK, a downstream molecule of XBP-1 activation (27), is significantly 
up-regulated in the ERp29-induced dormant cells. p58IPK was originally identified as a cellular 
inhibitor of the interferon-induced serine/threonine protein kinase (PKR) which is recruited by 
influenza virus to inhibit PKR function in eIF2α phosphorylation through a direct interaction with 
PKR (37, 38). Recent study further demonstrated that p58IPK can interact with and inhibit the PERK 
phosphorylation, leading to a decreased phosphorylation of eIF2α (29). In the ERp29-induced 
dormant cells, silencing of p58IPK stimulated eIF2α phosphorylation and activated the expression of 
ATF4/CHOP and cleavage of caspase-3 (Fig. 5A), leading to an increased cell apoptosis. This is 
further supported by the early studies that eIF2α phosphorylation mediated stress-induced apoptosis 
(39). Therefore, up-regulation of p58IPK may facilitate cell survival under stress in the ERp29-induced 
dormant cells by repressing eIF2α phosphorylation. It is well known that GADD34, a downstream 
target of the activated p-eIF2α, also inhibits eIF2α phosphorylation by feedback loop (40). 
Nevertheless, it should be noted that induction of p58IPK is directly regulated by ATF6 or 
IRE1/XBP-1-mediated arm of the UPR and is an upstream molecule that can directly bind to PERK to 
inactivate PERK/p-eIF2α (27, 41). Our studies provide a clue that induction of p58IPK by ERp29 may 
help to protect cells from the p-p38-activated excessive ER stress by de-phosphorylating eIF2α (42). 
As such, disturbing the signaling balance of p-p38-activated PERK/p-eIF2α and p58IPK-repressed 
PERK/p-eIF2α at the steady state could impair the dormancy in the ERp29-induced dormant cells. As 
demonstrated, activation of p-eIF2α/ATF4/CHOP pro-apoptotic pathway by silencing p58IPK 
correlated to the increased sensitivity of dormant cells to doxorubicin treatment (Fig. 5B). Collectively, 
our data indicate that p58IPK is an important coordinator in modulating the crosstalk between the 
ERp29-mediated ER stress and ER-dependent pro-apoptotic signaling by inhibiting eIF2α 
phosphorylation in the ERp29-induced dormant cells. 
In summary, we demonstrate the molecular mechanism underlying the ERp29-induced breast 
tumor cell dormancy. As illustrated in Figure 6, over-expression of ERp29 down-regulates the 
expression of uPAR/1-integrin/EGFR and subsequently activates p38 phosphorylation. Activation of 
p38 inhibits basal eIF2α expression, reduces cyclin D2 and increases p15 and p21, leading to G1 arrest. 
On the other hand, the up-regulated p58IPK in the ERp29-induced dormant cells suppresses the 
activation of p-p38/p-PERK/ p-eIF2α by repressing eIF2α phosphorylation, thus preventing cells from 
undergoing an ER-dependent apoptosis driven by extensive activation of ATF4/CHOP/caspase-3 
pathway. Consequently, p38 phosphorylation and p58IPK up-regulation play key roles in modulating 
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FIGURE 1. Over-expression of ERp29 decreases the level of uPAR/1-integrin/EGFR complex 
and activates p38 phosphorylation. A, The uPAR/1-integrin/EGFR complex is highly reduced in 
the ERp29-induced dormant cells (clone B and E) (left panel). In the dormant cells, Ets-1, a 
transcription factor of uPAR, was markedly reduced by ERp29 (right panel), leading to a 
down-regulation of uPAR. B, Over-expression of ERp29 in MDA-MB-231 cells (left panel) 
attenuates the expression of FAK and basal p38, but significantly stimulates p38 phosphorylation. 
Knock-down of ERp29 in MCF-7 cells (right panel) increases expression of basal p38 while 
reduces its phosphorylation. Total proteins from the vector-transfected control cells and 
ERp29-over-expressed dormant cells (clone B and E) were extracted and the expression of the 
indicated proteins was examined by Western blotting as described in “Materials and Methods”. 
The level of β-actin was used as a loading control. C, Zymography of MMPs. Cells were 
serum-starved for 24 h and the secreted MMPs were assayed by gelatin zymography as described 
in “Materials and Methods”. Note that MMP-9 activity is significantly reduced in the dormant 
cells (clone B).  
 
FIGURE 2. ERp29 results in cell cycle G1 arrest by affecting checkpoint protein expression. A, 
Over-expression of ERp29 significantly decreases cyclin D2 expression and increases p15 and p21 
expression (left panel) while silencing of ERp29 in MCF-7 cells reverses the expression patterns 
of these molecules (right panel), as assessed by Western blotting. B, p38 phosphorylation involves 
the ERp29-mediated down-regulation of cyclin D2 and up-regulation of p15 in dormant cells. The 
ERp29-induced dormant cells (clone B) were treated with p38 phosphorylation-specific inhibitor 
SB203580 (40µM) or DMSO (control) for 24h and the expression of proteins was analyzed by 
Western blotting as described in “Materials and Methods”. The cells treated with inhibitor show a 
decreased p38 phosphorylation, increased cyclin D2 and reduced p15 expression compared to the 
cells treated with DMSO. SB, SB203580. 
 
FIGURE 3. p38 phosphorylation involves the ERp29-mediated down-regulation of eIF2α. A, 
Expression of basal eIF2α is highly decreased while the relative phosphorylation of eIF2α (p- 
eIF2α/eIF2α) is similar in the dormant cells (clone B). Knockdown of ERp29 in MCF-7 cells 
results in an up-regulation of basal eIF2α and a moderate increase of the phosphorylation of eIF2α. 
B, Inhibition of p38 phosphorylation by inhibitor SB203580 increases expression of basal eIF2α, 




 cells compared to the DMSO-treated control cells. Cells were respectively treated with DMSO and 
inhibitor following the same procedure as described in Figure 2 and the expression of proteins was 
assessed by Western blotting. Data represent an average of fold changes of relative 
phosphorylation of eIF2α normalized to basal eIF2α from three independent experiments. SB, 
SB203580. 
 
FIGURE 4. ERp29 regulates the expression of p58IPK, PERK and ATF4. A, ERp29 highly 
up-regulates p58IPK.  Data represent a fold change of p58IPK after normalized to -actin, 
compared to the control cells. B, Effect of ERp29 on other molecules that response to UPR. 
Immunoblot analysis shows an up-regulation of PERK and BIP in the ERp29-induced dormant 
cells. However, BIP is also significantly expressed in the ERp29-knockdown MCF-7 cells (right 
panel). ATF4 expression is not highly increased in dormant cells, but instead, it is markedly 
increased in the ERp29-knockdown MCF-7 cells, implicating an activation of eIF2α downstream 
signal.  
 
FIGURE 5. Silencing of p58IPK stimulates eIF2α phosphorylation, activates eIF2α 
phosphorylation-dependent ATF4/CHOP pro-apoptotic pathway and increases 
doxorubicin-induced cell apoptosis. A, Silencing of p58IPK enhances eIF2α phosphorylation. The 
ERp29-induced dormant cells (clone B) and MCF-7 cells were respectively treated with 100nM of 
p58IPK-specific siRNA (p58IPK/siRNA) or scramble siRNA for 24h and the expression of 
proteins was analyzed by Western blotting. As indicated, reduction of p58IPK by siRNA markedly 
increased the phosphorylation of eIF2α without highly affecting the level of basal eIF2α. Data 
represent a fold change of relative phosphorylation of eIF2α in the p58IPK/siRNA-treated cells 
normalized to the control cells. B, Silencing of p58IPK activates ATF4\CHOP pathway and 
increases expression of cleaved caspase-3.  The ERp29-induced dormant cells and MCF-7 cells 
were treated as described above and the indicated protein expression was analyzed. The cleavage 
caspase-3 (17 and 12 kDa) was expressed in the p58IPK/siRNA treated cells. C, Silencing of 
p58IPK sensitizes both the ERp29-induced dormant cells and MCF-7 cells to DOX. Cells were 
treated with p58IPK /siRNA or scramble siRNA for 24h, followed by treatment with DOX (final 
conc. 200µg/ml) or DMSO for 24h. Cell viability was assessed using MTS as described in 
“Materials and Methods”. As indicated, p58IPK silence and DOX synergistically increased cell 
death in both types of cells. Data represent a mean of three independent experiments. Bars: 
standard deviation (SD); DOX, doxorubicin. * p< 0.01; ** p< 0.001 
 
FIGURE 6. Novel molecular mechanism of ERp29-induced cancer cell dormancy. In the 
ERp29-induced dormant cells, uPAR/1-integrin/EGFR complex is highly decreased, leading to 
activation of p38. p38 phosphorylation inhibits the expression of basal eIF2α and cyclin D2 and 
increases the expression of p15 and p21, thus causing G1 arrest. On the other hand, 
over-expression of ERp29 up-regulates p58IPK by enhancing XBP-1 splicing. The up-regulated 
p58IPK functionally counteracts the up-stream kinases of eIF2α to inhibit eIF2α phosphorylation 
and attenuate activation of p-PERK/p-eIF2α pathway. Reduction of p58IPK by RNA interference 




 pathway and cell apoptosis. Activation of p38 and up-regulation of p58IPK are the critical 
molecular events in maintaining the ERp29-induced cell dormancy. XBP-1u: unspliced XBP-1; 
XBP-1s; spliced XBP-1. XBP-1 is activated by deleting 26 nucleotides by a protein kinase and 
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Supplementary Figure 1 
 
 
Supplementary Figure 1. Immunofluorescent analysis of the expression of Ets-1 
and cyclin D2. A, Ets-1 (green) is expressed in both nucleus (red arrow) and cytoplasm 
(white arrow) in the vector-transfected MDA-MB-231 control cells. It is highly reduced in 
both nucleus and cytoplasm in the ERp29-induced dormant cells (clone B and E). B, 
Cyclin D2 (green) is expressed in both nucleus (red arrow) and cytoplasm (white arrow) 
in the vector-transfected MDA-MB-231 control cells  and is translocated from nucleus to 
cytoplasm to form aggregation (yellow arrow) in the ERp29-induced dormant cells (clone 
B and E). Nucleus are stained with DAPI (blue). 
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